WO2017197376A1 - Treatment of disease based on immune cell sequencing - Google Patents
Treatment of disease based on immune cell sequencing Download PDFInfo
- Publication number
- WO2017197376A1 WO2017197376A1 PCT/US2017/032593 US2017032593W WO2017197376A1 WO 2017197376 A1 WO2017197376 A1 WO 2017197376A1 US 2017032593 W US2017032593 W US 2017032593W WO 2017197376 A1 WO2017197376 A1 WO 2017197376A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- codon
- disease
- cancer
- mutations
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract description 23
- 201000010099 disease Diseases 0.000 title abstract description 20
- 210000002865 immune cell Anatomy 0.000 title description 15
- 238000012163 sequencing technique Methods 0.000 title description 15
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 39
- 230000001404 mediated effect Effects 0.000 claims abstract description 21
- 230000008685 targeting Effects 0.000 claims abstract description 12
- 230000006378 damage Effects 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims description 158
- 108020004705 Codon Proteins 0.000 claims description 76
- 108091034117 Oligonucleotide Proteins 0.000 claims description 63
- 201000006417 multiple sclerosis Diseases 0.000 claims description 62
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 53
- 230000035772 mutation Effects 0.000 claims description 50
- 108090000623 proteins and genes Proteins 0.000 claims description 50
- 239000000427 antigen Substances 0.000 claims description 43
- 108091007433 antigens Proteins 0.000 claims description 43
- 102000036639 antigens Human genes 0.000 claims description 43
- 210000004027 cell Anatomy 0.000 claims description 39
- 206010028980 Neoplasm Diseases 0.000 claims description 37
- 210000004602 germ cell Anatomy 0.000 claims description 35
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 31
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 27
- 239000012634 fragment Substances 0.000 claims description 25
- 208000016192 Demyelinating disease Diseases 0.000 claims description 21
- 230000028993 immune response Effects 0.000 claims description 19
- 238000012986 modification Methods 0.000 claims description 18
- 230000004048 modification Effects 0.000 claims description 18
- 108020004459 Small interfering RNA Proteins 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 13
- 239000002773 nucleotide Substances 0.000 claims description 13
- 125000003729 nucleotide group Chemical group 0.000 claims description 13
- 244000052769 pathogen Species 0.000 claims description 13
- 230000001717 pathogenic effect Effects 0.000 claims description 12
- 210000001519 tissue Anatomy 0.000 claims description 12
- 208000024891 symptom Diseases 0.000 claims description 11
- 230000014509 gene expression Effects 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 10
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 10
- 208000003435 Optic Neuritis Diseases 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 9
- 230000036210 malignancy Effects 0.000 claims description 9
- 208000008795 neuromyelitis optica Diseases 0.000 claims description 9
- 208000035473 Communicable disease Diseases 0.000 claims description 8
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 8
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 239000002105 nanoparticle Substances 0.000 claims description 7
- 210000005259 peripheral blood Anatomy 0.000 claims description 7
- 239000011886 peripheral blood Substances 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 7
- 208000009174 transverse myelitis Diseases 0.000 claims description 7
- 210000004884 grey matter Anatomy 0.000 claims description 6
- 238000007918 intramuscular administration Methods 0.000 claims description 6
- 238000007913 intrathecal administration Methods 0.000 claims description 6
- 238000001990 intravenous administration Methods 0.000 claims description 6
- 239000013610 patient sample Substances 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- 238000007920 subcutaneous administration Methods 0.000 claims description 6
- 208000011231 Crohn disease Diseases 0.000 claims description 5
- 208000024781 Immune Complex disease Diseases 0.000 claims description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 5
- 206010054000 Type II hypersensitivity Diseases 0.000 claims description 5
- 206010047115 Vasculitis Diseases 0.000 claims description 5
- 241000700605 Viruses Species 0.000 claims description 5
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 238000003384 imaging method Methods 0.000 claims description 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 5
- 230000008026 type II hypersensitivity Effects 0.000 claims description 5
- 230000028063 type III hypersensitivity Effects 0.000 claims description 5
- 208000025883 type III hypersensitivity disease Diseases 0.000 claims description 5
- 239000003446 ligand Substances 0.000 claims description 4
- 230000002194 synthesizing effect Effects 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 3
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000002699 Digestive System Neoplasms Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 241000233866 Fungi Species 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 201000000582 Retinoblastoma Diseases 0.000 claims description 2
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 201000009036 biliary tract cancer Diseases 0.000 claims description 2
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 2
- 201000000220 brain stem cancer Diseases 0.000 claims description 2
- 201000007455 central nervous system cancer Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 208000024519 eye neoplasm Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 2
- 201000004962 larynx cancer Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 201000005962 mycosis fungoides Diseases 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 201000008106 ocular cancer Diseases 0.000 claims description 2
- 201000005443 oral cavity cancer Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 244000045947 parasite Species 0.000 claims description 2
- 201000002628 peritoneum cancer Diseases 0.000 claims description 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 2
- 201000003804 salivary gland carcinoma Diseases 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 210000001130 astrocyte Anatomy 0.000 claims 4
- 230000003211 malignant effect Effects 0.000 abstract description 6
- 229940124691 antibody therapeutics Drugs 0.000 abstract description 5
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 239000003814 drug Substances 0.000 description 24
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 description 23
- 239000000203 mixture Substances 0.000 description 21
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 description 15
- 206010071068 Clinically isolated syndrome Diseases 0.000 description 12
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 description 12
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 description 11
- 229940124597 therapeutic agent Drugs 0.000 description 11
- 239000000839 emulsion Substances 0.000 description 10
- 238000009472 formulation Methods 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 206010067063 Progressive relapsing multiple sclerosis Diseases 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 7
- 238000002595 magnetic resonance imaging Methods 0.000 description 7
- 230000001575 pathological effect Effects 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 6
- 108010050904 Interferons Proteins 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 229940079322 interferon Drugs 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000005713 exacerbation Effects 0.000 description 4
- -1 for example Proteins 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 210000000278 spinal cord Anatomy 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 206010012305 Demyelination Diseases 0.000 description 3
- 101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 description 3
- 102000006386 Myelin Proteins Human genes 0.000 description 3
- 108010083674 Myelin Proteins Proteins 0.000 description 3
- 208000007542 Paresis Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 230000005875 antibody response Effects 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000007385 chemical modification Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000004547 gene signature Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000000693 micelle Substances 0.000 description 3
- 210000005012 myelin Anatomy 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 208000004296 neuralgia Diseases 0.000 description 3
- 230000000626 neurodegenerative effect Effects 0.000 description 3
- 230000007971 neurological deficit Effects 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000035657 Abasia Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 108010072051 Glatiramer Acetate Proteins 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 108010005716 Interferon beta-1a Proteins 0.000 description 2
- 108010005714 Interferon beta-1b Proteins 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 208000008238 Muscle Spasticity Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 201000007201 aphasia Diseases 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000003376 axonal effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000003210 demyelinating effect Effects 0.000 description 2
- 229960004419 dimethyl fumarate Drugs 0.000 description 2
- 238000011979 disease modifying therapy Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 229960000556 fingolimod Drugs 0.000 description 2
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 238000007481 next generation sequencing Methods 0.000 description 2
- 229950005751 ocrelizumab Drugs 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002250 progressing effect Effects 0.000 description 2
- 238000012175 pyrosequencing Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 208000018198 spasticity Diseases 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- UTNUDOFZCWSZMS-YFHOEESVSA-N teriflunomide Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC=C(C(F)(F)F)C=C1 UTNUDOFZCWSZMS-YFHOEESVSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 206010054196 Affect lability Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010014223 Armadillo Domain Proteins Proteins 0.000 description 1
- 102000016904 Armadillo Domain Proteins Human genes 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102100029945 Beta-galactoside alpha-2,6-sialyltransferase 1 Human genes 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100025221 CD70 antigen Human genes 0.000 description 1
- 102100027221 CD81 antigen Human genes 0.000 description 1
- 102100027217 CD82 antigen Human genes 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- 206010008072 Cerebellar syndrome Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 206010009346 Clonus Diseases 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 102100032768 Complement receptor type 2 Human genes 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 108010025905 Cystine-Knot Miniproteins Proteins 0.000 description 1
- 241000289632 Dasypodidae Species 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 1
- 208000003164 Diplopia Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 description 1
- 241001635598 Enicostema Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 241001539473 Euphoria Species 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 208000034347 Faecal incontinence Diseases 0.000 description 1
- 208000021663 Female sexual arousal disease Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100033808 Glycoprotein hormone alpha-2 Human genes 0.000 description 1
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000863864 Homo sapiens Beta-galactoside alpha-2,6-sialyltransferase 1 Proteins 0.000 description 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 1
- 101000914469 Homo sapiens CD82 antigen Proteins 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 1
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 description 1
- 101000907904 Homo sapiens Endoribonuclease Dicer Proteins 0.000 description 1
- 101001069261 Homo sapiens Glycoprotein hormone alpha-2 Proteins 0.000 description 1
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 description 1
- 101000878602 Homo sapiens Immunoglobulin alpha Fc receptor Proteins 0.000 description 1
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 description 1
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 description 1
- 101000605020 Homo sapiens Large neutral amino acids transporter small subunit 1 Proteins 0.000 description 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
- 101000984196 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily A member 5 Proteins 0.000 description 1
- 101000984190 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 1 Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101000633778 Homo sapiens SLAM family member 5 Proteins 0.000 description 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102100038005 Immunoglobulin alpha Fc receptor Human genes 0.000 description 1
- 206010022520 Intention tremor Diseases 0.000 description 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 1
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 101150008942 J gene Proteins 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- 102100025584 Leukocyte immunoglobulin-like receptor subfamily B member 1 Human genes 0.000 description 1
- 208000020933 Lhermitte sign Diseases 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 241001115401 Marburgvirus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010027626 Milia Diseases 0.000 description 1
- 206010027925 Monoparesis Diseases 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 241000588621 Moraxella Species 0.000 description 1
- 208000007379 Muscle Hypotonia Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 208000003926 Myelitis Diseases 0.000 description 1
- 208000002033 Myoclonus Diseases 0.000 description 1
- 206010028632 Myokymia Diseases 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 206010056677 Nerve degeneration Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- SKWPGOJVPWRYQJ-UHFFFAOYSA-N OP(O)(O)=O.OP(O)(S)=S Chemical compound OP(O)(O)=O.OP(O)(S)=S SKWPGOJVPWRYQJ-UHFFFAOYSA-N 0.000 description 1
- 206010063534 Ocular dysmetria Diseases 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010033885 Paraparesis Diseases 0.000 description 1
- 206010033892 Paraplegia Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 108010079855 Peptide Aptamers Proteins 0.000 description 1
- 206010034701 Peroneal nerve palsy Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 206010034962 Photopsia Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920006022 Poly(L-lactide-co-glycolide)-b-poly(ethylene glycol) Polymers 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 description 1
- 206010037714 Quadriplegia Diseases 0.000 description 1
- 108010065868 RNA polymerase SP6 Proteins 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 102100029216 SLAM family member 5 Human genes 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 102100038081 Signal transducer CD24 Human genes 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000014604 Specific Language disease Diseases 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 102100024554 Tetranectin Human genes 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010064899 Vulvovaginal mycotic infection Diseases 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 241000907316 Zika virus Species 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000000823 artificial membrane Substances 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 229940057415 aubagio Drugs 0.000 description 1
- 229940003504 avonex Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 108010028263 bacteriophage T3 RNA polymerase Proteins 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000032257 benign familial neonatal 1 seizures Diseases 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940021459 betaseron Drugs 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 229940038717 copaxone Drugs 0.000 description 1
- 210000000877 corpus callosum Anatomy 0.000 description 1
- 238000003066 decision tree Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 201000003892 detrusor sphincter dyssynergia Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 229940077362 extavia Drugs 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000007672 fourth generation sequencing Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000000799 fusogenic effect Effects 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 201000006592 giardiasis Diseases 0.000 description 1
- 229960003776 glatiramer acetate Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 206010019465 hemiparesis Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 102000051308 human DICER1 Human genes 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006028 immune-suppresssive effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940028435 intralipid Drugs 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229940047834 lemtrada Drugs 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 125000001921 locked nucleotide group Chemical group 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical group CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 210000002500 microbody Anatomy 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002539 nanocarrier Substances 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 229940064696 nutrilipid Drugs 0.000 description 1
- 206010029864 nystagmus Diseases 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 206010030875 ophthalmoplegia Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 208000021090 palsy Diseases 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 108010027737 peginterferon beta-1a Proteins 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910000065 phosphene Inorganic materials 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- CGPPXVAUDMUIPK-UHFFFAOYSA-N phosphoric acid trihydroxy(sulfanylidene)-lambda5-phosphane Chemical compound OP(O)(O)=O.OP(O)(O)=S CGPPXVAUDMUIPK-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000003720 plasmablast Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229940007060 plegridy Drugs 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 230000000272 proprioceptive effect Effects 0.000 description 1
- 208000022749 pupil disease Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229940038850 rebif Drugs 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000004370 retrospective diagnosis Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012706 support-vector machine Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940121136 tecfidera Drugs 0.000 description 1
- 229960000331 teriflunomide Drugs 0.000 description 1
- 238000011191 terminal modification Methods 0.000 description 1
- 108010013645 tetranectin Proteins 0.000 description 1
- 239000005451 thionucleotide Substances 0.000 description 1
- SBUXRMKDJWEXRL-ZWKOTPCHSA-N trans-body Chemical compound O=C([C@@H]1N(C2=O)[C@H](C3=C(C4=CC=CC=C4N3)C1)CC)N2C1=CC=C(F)C=C1 SBUXRMKDJWEXRL-ZWKOTPCHSA-N 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 201000002311 trypanosomiasis Diseases 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 229940079023 tysabri Drugs 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 206010047385 vestibular ataxia Diseases 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Definitions
- the present invention relates to treatment of disease, including treatment of antibody-mediated autoimmune disorders, as well as treatment of other conditions in which antibody therapeutics can be beneficial for targeting destruction of foreign or malignant cells.
- the invention provides methods for treating antibody- mediated autoimmune disease, including demyelinatng diseases, as well as treatment of other conditions in which antibody therapeutics can be beneficial for targeting desctruction of foreign or malignant cells.
- the methods involve determining nucleotide sequences in a patient sample for a plurality of immunoglobulin-encoding genes or transcripts, and particularly the nucleotide sequences encoding at least a portion of the complementarity-determining regions (CDRs), which are representative of the antigen- binding specificity.
- CDRs complementarity-determining regions
- the patient exhibits one or more symptoms of a neurodegenerative or demyelinating disorder, such as multiple sclerosis (MS), such as relapsing remitting MS (RRMS), secondary progressive MS (SPMS), primary progressive MS (PPMS), or progressive relapsing MS (PRMS).
- a neurodegenerative or demyelinating disorder such as multiple sclerosis (MS), such as relapsing remitting MS (RRMS), secondary progressive MS (SPMS), primary progressive MS (PPMS), or progressive relapsing MS (PRMS).
- RRMS relapsing remitting MS
- SPMS secondary progressive MS
- PPMS primary progressive MS
- PRMS progressive relapsing MS
- the patient has clinically isolated syndrome (CIS), and is at risk of progressing to MS.
- the patient has optic neuritis, neuromyelitis optica, or transverse myelitis.
- the invention can be applied to other autoimmune conditions as described herein.
- the methods involve determining an antibody repertoire of a patient, for example, by amplification and sequencing of antibody genes or transcripts from patient B cells.
- antibody heavy chains e.g., variable heavy chain sequences
- paired heavy and light chains are sequenced.
- antibodies of interest are cloned and evaluated by immunochemistry with samples that comprise the autoantigen (e.g., tissue, cell sample, or purified or partially purified antigen), to confirm that antibodies of interest are likely involved in the autoimmune pathology.
- autoantigen e.g., tissue, cell sample, or purified or partially purified antigen
- the patient has a demyelinating disease such as MS, and mutation at defined codons in VH4 antibodies are evaluated, to identify the presence, absence, or relative level of VH4 antibodies that are indicative of MS or other demyelinating disease or inflammatory disease of the CNS.
- VH4 antibodies having mutations in least 2 codons selected from 3 IB, 32, 40, 56, 57, 60, 81, and 89 are selected as being potentially pathological antibodies for the patient's disease.
- the invention involves designing a therapeutic agent to target the identified sequences.
- a therapeutic agent to target the identified sequences.
- the therapeutic agent(s) may be antisense oligonucleotides or siRNAs specific for one or more the sequences identified.
- the therapeutic agents include one or more antibodies or fragments thereof, modified to lack immune effector functions relevant to the disease processes (e.g., inflammation and/or demyelination).
- the oligonucleotides and antibodies may be formulated as a variety of pharmaceutical compositions, including for administration by a variety of routes.
- the invention provides methods for producing therapeutic antibodies to target destruction of unwanted cells, including malignant cells and pathogens.
- B cells and corresponding antibodies are identified that can direct a productive or effective antibody response against the unwanted cells.
- a first population of B cells from one or more subjects displaying an immune response against a malignancy or infectious disease is provided, and the corresponding antibody genetics evaluated against antibodies from a second population of B cells that do not exhibit the immune response of interest.
- the second population of B cells can be from the same subjects as the first population, or from different subjects.
- B cells can be isolated from tumor tissue or infected tissue of patients exhibiting a productive immune response, and resulting antibody genetics evaluated against antibody sequences from other B cell populations.
- the antibodies or antigen-binding fragments or portions thereof identified as involved in the immune response of interest are cloned, recombinantly produced, and formulated for administration to patients.
- the present invention relates to treatment of disease, including treatment of antibody-mediated autoimmune disorders, as well as treatment of other conditions in which antibody therapeutics can be beneficial for targeting destruction of foreign or malignant cells.
- the present invention employs a biologically-directed approach to identify key pathophysiological antibody sequences and integrate them into a novel class of protein or oligonucleotide therapies.
- the present invention in various aspects provides therapy for demyelinating diseases, such as multiple sclerosis, without exposing the patient to the risk of a systemic immune cell ablation.
- the invention provides methods for treating autoimmune diseases, such as demyelinatng diseases.
- the methods involve determining nucleotide sequences in a patient sample for a plurality of immunoglobulin-encoding genes or transcripts, and particularly the nucleotide sequences encoding at least a portion of the complementarity-determining region (CDR), which are representative of the antigen-binding specificity.
- CDR complementarity-determining region
- Exemplary antibody-mediated autoimmune diseases in which the invention finds use include multiple sclerosis, neuromyelitis optica, optic neuritis, transverse myelitis, acute disseminated encephalitis, systemic lupus erythematosus (SLE), rheumatoid arthritis, Sjogren's disease, psoriasis, vasculitis, Crohn's disease, and inflammatory bowel disease, among others.
- the autoimmune disease is characterized by type II or type III hypersensitivity.
- the autoimmune disease is a demyelinating disease.
- the patient exhibits one or more symptoms of a neurodegenerative or demyelinating disorder, such as multiple sclerosis (MS).
- a neurodegenerative or demyelinating disorder such as multiple sclerosis (MS).
- MS is one of the most common diseases of the central nervous system (brain and spinal cord). It is an inflammatory condition associated with demyelination, or loss of the myelin sheath. Myelin, a fatty material that insulates nerves, acts as insulator in allowing nerves to transmit impulses from one point to another.
- the loss of myelin is accompanied by a disruption in the ability of the nerves to conduct electrical impulses to and from the brain and this produces the various symptoms of MS, such as impairments in vision, muscle coordination, strength, sensation, speech and swallowing, bladder control, sexuality and cognitive function.
- the plaques or lesions where myelin is lost appear as hardened, scar-like areas. These scars appear at different times and in different areas of the brain and spinal cord.
- the patient has relapsing remitting MS (RRMS), secondary progressive MS (SPMS), primary progressive MS (PPMS), or progressive relapsing MS (PRMS).
- the patient has clinically isolated syndrome (CIS), and is at risk of progressing to MS.
- the patient has optic neuritis, neuromyelitis optica, or transverse myelitis.
- the methods involve determining an antibody repertoire of a patient, for example, by amplification and sequencing of antibody genes or transcripts from patient B cells.
- Methods for determining an antibody repertoire by nucleotide sequencing have been described in US 2014/0371103 and US 2014/0357500, which are each hereby incorporated by reference in their entireties. Sequencing methods are generally in high-throughput, but can employ any sequencing platform including pyrosequencing, sequencing-by-synthesis, or nanopore sequencing platform, among others.
- antibody heavy chains or portions thereof preferably comprising one or more CDRs can be sequenced and evaluated to identify pathological antibody sequences.
- paired heavy and light chains are clonally amplified and sequenced. Sequencing can take place by any known sequencing process, including high throughput sequencing-by-synthesis or pyrosequencing.
- isolated immune cells can be encapsulated in water in oil emulsions to create individual picoliter compartments containing a single immune cell or less per droplet. Millions of cells can be processed for each patient allowing high throughput in single cell sequencing technology. Micron scale paramagnetic beads harboring oligonucleotides complementary to the VH and VL antibody chains are introduced during the emulsion process.
- These beads may carry long degenerate barcodes such that each bead can confer a unique identity code.
- the millions of single immune cells are lysed inside the emulsion and the antibody transcripts are reverse transcribed using the barcoded bead primers, followed by PCR amplification of the VH and VL chains.
- Each VH and VL chain stemming from a single immune cell can be virtually linked to each other with the same barcode identity.
- the VH and VL chains are then recovered from the emulsion, and PCR enriched in order to add next-generation sequencing (NGS) tags.
- NGS next-generation sequencing
- the library can be sequenced using a high throughput sequencing platform followed by analysis of repertoire diversity, antibody frequency, CDR3 characterization, somatic hypermutation phylogeny analysis, etc.
- a database of correctly matched VH and VL pairs can be generated by deconvoluting the bead barcode sequences. Because each single immune cells were isolated in their respective emulsion droplets, for each barcode observed twice, the transcripts sequenced originated from a same emulsion droplets and therefore from a unique single cell.
- select VH and VL sequences of interest can be optionally cloned into antibody expression vectors and co-transfected and produced for characterization.
- antibodies of interest can be evaluated by immunochemistry with a source of autoantigen, which can be a tissue, cell or cell line, or purified or partially purified antigen.
- the source of autoantigen can be brain or CNS samples, and staining patterns can be evaluated for staining of white and gray matter. This process can confirm that the antibody is likely involved in disease pathology.
- the selected antibody binds an antigen in human and/or mouse gray matter.
- antibody-producing immune cells can be isolated from the blood or other biological samples of the patient.
- the lymphocyte pool can be enriched for the desired immune cells by any suitable method, such as screening and sorting the cells using fluorescence-activated cell sorting (FACS), magnetic activated cell sorting (MACS), panning or other screening method to generate a plurality of immune cells from a sample.
- FACS fluorescence-activated cell sorting
- MCS magnetic activated cell sorting
- panning or other screening method to generate a plurality of immune cells from a sample.
- B cells are recovered from a cerebrospinal fluid sample from the patient, or alternatively, the starting material is peripheral blood.
- the peripheral blood cells can be enriched for B cells or plasmablasts.
- VH1 through VH6 The germline VH genes are separated into at least six families (VH1 through VH6) based on DNA nucleotide sequence identity of the first 95 to 101 amino acids. Members of the same family typically have 80% or more sequence identity, whereas members of different families have less than 70% identity. These families range in size from one VH6 gene to an estimated greater than 45 VH3 genes.
- VH4 family genes which are of interest for demyelinating diseases, contain 9 different members: 4-04, 4-28, 4-30, 4-31, 4-34, 4-39, 4-59, 4-61, 4-B.
- amplification of immune cell genetic material e.g. reverse transcription polymerase chain reaction (RT-PCR) is employed to generate cDNA amplification of immune cell genetic material.
- the immunoglobulin genes can be obtained from genomic DNA or mRNA of immune cells.
- RNA can be heavy chain (V, D, J segments), or light chain (V, J segments), or portions thereof.
- the starting material is RNA from immune cells composed of V, D, J gene segments.
- the method amplifies and/or sequences IgG antibodies
- one or more other isotypes can be sequenced alternatively or in addition, such as IgM, IgA, IgE and IgD isotypes, as well as antibody subtype.
- the sequencing can be specific for one or more of VHl, VH2, VH3, VH4, VH5, or VH6.
- VH4 antibodies are sequenced, which are considered to play a role in the pathology of MS and related neurodegenerative diseases. Processes for sequencing VH4 sequences are disclosed in US 2014/0371103, which is hereby incorporated by reference.
- mutation at defined codons in VH4 antibodies are evaluated, to identify the presence, absence, or relative level of VH4 antibodies that are indicative of MS or other demyelinating disease or inflammatory disease of the CNS.
- U. S. Patent No. 8,394,583 (the entire disclosure of which is hereby incorporated by reference) describes a biomarker for conversion from CIS to clinically definite MS (CDMS) in the antibody genetics of Vn4-utilizing B cells.
- Antibodies having mutations in least 2 codons selected from 31B, 32, 40, 56, 57, 60, 81, and 89 are selected as being potentially pathological antibodies for the patient's disease.
- VH4 genes or transcripts can include one or more (or all) subfamily genes, for example, 4-04, 4-28, 4- 30, 4-31, 4-34, 4-39, 4-59, 4-61, and 4-B. Further, VH4 signatures indicative of neuromyelitis optica (NMO) are described in WO 2013/059417, the entire contents of which are hereby incorporated by reference.
- signature VH4 sequences generally comprise two or more mutations at codon positions 3 IB, 32, 40, 56, 57, 60, 81, and 89.
- the VH4 antibody comprises at least 3, or at least 4, or at least 5, or at least 6 mutations with respect to the germline sequence at these positions.
- the VH4 antibody comprises mutations at one or more of codons 32, 40, 57, 60, and 89 with respect to the germline sequence.
- the VH4 antibody comprises mutations at two or more of codons 56, 57, and 81 with respect to the germline sequence.
- the VH4 antibody comprises mutations at two or more of codons 40, 56, 81, and 89 with respect to the germline sequence.
- exemplary mutations at codon 3 IB include R, N, D, P, K, G, A, and T; exemplary mutations at codon 40 include S, L, and A; exemplary mutations at codon 56 include R, G, N, T, Y, H, D, and K; exemplary mutation at codon 57 include A, I, D, and S; exemplary mutations at codon 81 include N, R, and M; exemplary mutations at codon 89 include F, I, R, and L.
- the methods are however not limited to these mutations or sets of mutations described in WO 2015/070009.
- Other antibody signatures that are indicative of other conditions can be identified by sequencing the antibody repertoire of a suitable patient cohort or isolated B cell population of interest, and comparing the sequences to a control B cell population.
- the control B cell population does not exhibit the reactivity of interest, and in various embodiments may be isolated from healthy controls, or controls that include other inflammatory or degenerative diseases, or from locations of the body not affected by the disease of interest.
- antibody gene signatures can be identified using known classifier algorithms including, without limitation: Principal Components Analysis, Naive Bayes, Support Vector Machines, Nearest Neighbors, Decision Trees, Logistic, Artificial Neural Networks, Penalized Logistic Regression, and Rule-based schemes.
- classifier algorithms including, without limitation: Principal Components Analysis, Naive Bayes, Support Vector Machines, Nearest Neighbors, Decision Trees, Logistic, Artificial Neural Networks, Penalized Logistic Regression, and Rule-based schemes.
- the predictions from multiple models can be combined to generate an overall prediction.
- the process for preparing a suitable class predictor is reviewed in R. Simon, Diagnostic and prognostic prediction using gene expression profiles in high-dimensional microarrav data. British Journal of Cancer (2003) 89, 1599-1604, which review is hereby incorporated by reference in its entirety.
- Antibody signatures can include mutational frequency at select codons (usually in CDR regions of heavy and/or light chains), identity and/or frequency of amino acid substitutions (e.g., including analysis of conserved or non-conserved substitutions), antibody isotype, and V-D-J gene usage, for example.
- the invention involves designing a therapeutic agent to target the identified antibody sequences.
- a therapeutic agent to target the identified antibody sequences.
- from 1 to about 20, or from 1 to about 10, or from 1 to about 5 (e.g., 1, 2, 3, 4, or 5) sequences are identified for targeting.
- the therapeutic agent may be one or more antisense oligonucleotides or siRNAs specific for one or more the sequences identified.
- the therapeutic agent is a recombinant antibody or antigen-binding fragment or portion thereof.
- Antisense oligonucleotides are typically in the range of 8 to 30 nucleotides in length, and 12 to 25 nucleotides in some embodiments, although the invention is not strictly tied to any particular size.
- oligonucleotides can be designed that are complementary to the variable heavy or variable light sequences in regions harboring the antibody gene signature.
- the oligonucleotide can be complementary to an antibody transcript in a region containing at least two codon mutations that are indicative of the disease.
- the oligonucleotide is complementary to an antibody transcript in a region containing at least three or at least four codon mutations that are indicative of the disease.
- antibody-encoding transcripts are identified that have at least 2, 3, or 4 mutations in the variable region that are indicative of disease, and which are within 20 nucleotides.
- a VH4 region of no more than about 25 or about 20 nucleotides, and within codons 3 IB to 89 of VH4, is identified that contains 2, 3, 4, or 5 (or more) signature mutations.
- These antibody-encoding transcripts are particularly suitable for antisense therapeutics.
- Oligonucleotide sequences are further identified that exhibit an appropriate Tm for therapeutic application, which can be further adjusted by nucleotide modifications are further described below.
- the same transcript is targeted by at least two antisense oligonucleotides, to thereby target additional regions harboring the antibody gene signature.
- siRNA(s) are designed to inhibit expression of the identified gene sequences. Structure, formulation, and delivery of siRNAs are described, for example, in US 2014/0161894, US 2014/0024699, US 2015/0197746, and US 2016/0076040, which are hereby incorporated by reference in their entireties. See also, Fakhr E. et al, Precise and efficient siRNA design: a key point in competent gene silencing. Cancer Gene Ther. 2016 Apr;23(4):73-82. Generally, design of siRNAs includes analysis of factors such as distance of target region to transcription start site, nucleotide composition, potential for off-target effects, secondary structures in the target site and siRNA, and the presence of asymmetry and energy valley within the siRNA.
- oligonucleotides such as antisense oligonucleotides or siRNAs
- modeling programs such as Foldsplit may be used to design antisense oligonucleotides (see Sczakiel G., et al (1993) Computer-aided search for effective antisense RNA target sequences of the human immunodeficiency virus type 1. Antisense Res. Dev. 3, 45-52).
- Algorithms for designing siRNAs are also known and include, without limitation, the Whitehead siRNA Selection Web Server (http://jura.wi.mit.edu/bioc/siRNA) as well as others described in Boese Q. et al, (2005) Mechanistic insights aid computational short interfering RNA design. Methods Enzvmol. 392:73-96.
- Oligonucleotide therapeutics may contain one or more chemical modifications to impart stability and/or increase affinity for the target site, among other advantages.
- exemplary chemical modifications include backbone modifications (e.g., phosphorothioate or phosphorodiamidate morpholino), as well as 2' modifications (e.g., 2' O-methyl or 2' halo) and bridging modifications (e.g., locked nucleic acid, or other 2' to 4' bridge structure), base modifications, and/or cap structures.
- backbone modifications e.g., phosphorothioate or phosphorodiamidate morpholino
- 2' modifications e.g., 2' O-methyl or 2' halo
- bridging modifications e.g., locked nucleic acid, or other 2' to 4' bridge structure
- the oligonucleotides may include at least one locked nucleotide (LNA), as described, for example, in U. S. Patent Nos. 6,268,490, 6,316, 198, 6,403,566, 6,770,748, 6,998,484, 6,670,461, and 7,034, 133, all of which are hereby incorporated by reference in their entireties.
- LNA locked nucleotide
- the oligonucleotide further comprises at least one terminal modification or "cap".
- the cap may be a 5' and/or a 3 '-cap structure.
- the terms “cap” or “end-cap” include chemical modifications at either terminus of the oligonucleotide (with respect to terminal ribonucleotides), and including modifications at the linkage between the last two nucleotides on the 5' end and the last two nucleotides on the 3' end.
- the cap structure may increase resistance of the oligonucleotide to exonucleases without compromising molecular interactions with the RNA target. Such modifications may be selected on the basis of their increased potency in vitro or in vivo.
- the cap can be present at the 5'-terminus (5'-cap) or at the 3'-terminus (3'-cap) or can be present on both ends.
- the 5'- and/or 3 '-cap is independently selected from phosphorothioate monophosphate, abasic residue (moiety), phosphorothioate linkage, 4'-thio nucleotide, carbocyclic nucleotide, phosphorodithioate linkage, inverted nucleotide or inverted abasic moiety (2'-3' or 3 '- 3'), phosphorodithioate monophosphate, and methylphosphonate moiety.
- the oligonucleotide may contain one or more phosphorothioate linkages. Phosphorothioate linkages have been used to render oligonucleotides more resistant to nuclease cleavage.
- the polynucleotide may be partially phosphorothioate- linked, for example, phosphorothioate linkages may alternate with phosphodiester linkages. In certain embodiments, however, the oligonucleotide is fully phosphorothioate-linked. In other embodiments, the oligonucleotide has from one to five or one to three phosphate linkages.
- the oligonucleotide may include one or more morpholino nucleotides.
- the oligonucleotide may include one or more peptide nucleic acids (PNAs), which contain a peptide-based backbone rather than a sugar-phosphate backbone.
- PNAs peptide nucleic acids
- oligonucleotides may be produced by a variety of techniques known in the art. For example, the synthesis of oligonucleotides, including modified polynucleotides, by solid phase synthesis is well known and is reviewed by Caruthers et al, New Chemical Methods for Synthesizing Polynucleotides. Nucleic Acids Symp. Ser., (7):215-23 (1980) which is hereby incorporated by reference in its entirety.
- oligonucleotides for example, siRNA
- the oligonucleotide may be incorporated within a variety of macromolecular assemblies or compositions. Such complexes for delivery may include a variety of liposomes, nanoparticles, and micelles, formulated for delivery to a patient.
- the oligonucleotides are incorporated within nanoparticles.
- the oligonucleotides may be complexed with lipids thus forming lipid nanoparticles (LNPs).
- the oligonucleotides may be complexed with polymeric nanocarriers to form polymeric nanoparticles.
- Polymeric nanoparticles may be formed from PLA or PLGA, PLA-PEG, PLGA-PEG, or combinations thereof.
- the complexes may include one or more fusogenic or lipophilic molecules to initiate cellular membrane penetration.
- the oligonucleotide may further comprise a pendant lipophilic group to aid cellular delivery, such as those described in WO 2010/129672, which is hereby incorporated by reference.
- the oligonucleotides are conjugated to peptides, antibodies, polymers, ligands, and/or aptamers for targeted delivery.
- the oligonucleotides may be conjugated to positively charged polymers.
- positively charged polymers examples include peptides, such as arginine rich peptides or TAT sequence.
- Another example of positively charged polymers is polyethylenimine (PEI) with multiple positively charged amine groups in its branched or unbranched chains.
- PEI polyethylenimine
- the oligonucleotides or complexes comprising the same are targeted for delivery to B cells.
- the oligonucleotides may be associated with a B-cell targeting ligand.
- the oligonucleotides or complexes comprising the same may be associated with an antibody that recognizes a B-cell marker such as CD10, CD19, CD20, CD21, CD22, CD23, CD24, CD37, CD38, CD39, CD40, CD70, CD72, CD73, CD74, CDw75, CDw76, CD77, CD78, CD79a/b, CD80, CD81, CD82, CD83, CD84, CD85, CD86, CD89, CD98, CD126, CD127, CDwl30, CD138, or CDwl50.
- a B-cell marker such as CD10, CD19, CD20, CD21, CD22, CD23, CD24, CD37, CD38, CD39, CD40, CD70, CD72, CD73, CD74, CDw75, CDw76, CD77, CD78, CD79a/b, CD80, CD81, CD82, CD83, CD84, CD85, CD86, CD89, CD98, CD126, CD127,
- compositions comprising an effective amount of the oligonucleotide(s) further comprise a pharmaceutically-acceptable carrier or diluent.
- the composition or formulation may employ a plurality of therapeutic oligonucleotides, including at least one described herein.
- the composition or formulation may employ at least about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, or about 10 oligonucleotides according to the present disclosure.
- the compositions may include one or more oligonucleotides targeting the signature VH4 sequences unique to a patient.
- the oligonucleotides of the invention may be formulated as a variety of pharmaceutical compositions.
- Pharmaceutical compositions will be prepared in a form appropriate for the intended application. Generally, this entails preparing compositions that are essentially free of pyrogens, as well as other impurities that could be harmful to humans or animals.
- Exemplary delivery/formulation systems include colloidal dispersion systems, macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes.
- fat emulsions that are suitable for delivering the nucleic acids of the invention include Intralipid®, Liposyn®, Liposyn® II, Liposyn® III, Nutrilipid, and other similar lipid emulsions.
- An exemplary colloidal system for use as a delivery vehicle in vivo is a liposome (i.e., an artificial membrane vesicle). The preparation and use of such systems is well known in the art. Exemplary formulations are also disclosed in U.S. Patent No. 5,981,505; U. S. Patent No. 6,217,900; U.S. Patent No. 6,383,512; U.S. Patent No. 5,783,565; U. S. Patent No. 7,202,227; U.S.
- Patent No. 6,379,965 U.S. Patent No. 6,127,170; U. S. Patent No. 5,837,533; U. S. Patent No. 6,747,014; and WO 2003/093449, which are hereby incorporated by reference in their entireties.
- compositions and formulations may employ appropriate salts and buffers to render delivery vehicles stable and allow for uptake by target cells.
- Aqueous compositions comprise an effective amount of the delivery vehicle comprising the oligonucleotide (e.g. liposomes or other complexes), dissolved or dispersed in a pharmaceutically acceptable carrier or aqueous medium.
- pharmaceutically acceptable carrier may include one or more solvents, buffers, solutions, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like acceptable for use in formulating pharmaceuticals, such as pharmaceuticals suitable for administration to humans. The use of such media and agents for pharmaceutically active substances is well known in the art.
- the present invention further relates to synthesizing one or more antibodies or antigen-binding fragments thereof encoded by identified antibody sequences indicative of the patient's disease.
- the antibodies are VH4 antibodies.
- the antibodies or antigen- binding fragments are cloned from the identified sequences, and expressed and recovered from a cell culture system.
- the antibodies, generaly lacking a functional Fc are delivered to a patient to reduce or eliminate symptoms of the autoimmune or demyelinating disease, for example, by blocking the interaction of the endogenous autoantibodies with target tissue.
- the present invention provides antibodies or anti-binding fragments thereof that bind to and neutralize the autoantibodies comprising the signature antibody sequences, thereby reducing or eliminating symptoms of the autoimmune disease.
- one or more antibody fragment or antigen-binding molecules are prepared against the identified antibodies.
- Each heavy chain includes one variable region (e.g., VH) and at least three constant regions (e.g., CHI, CH2 and CH3), and each light chain includes one variable region (VL) and one constant region (CL).
- the variable regions determine the specificity of the antibody.
- Each variable region comprises three hypervariable regions also known as complementarity determining regions (CDRs) flanked by four relatively conserved framework regions (FRs).
- CDR1, CDR2, and CDR3 contribute to the antibody binding specificity.
- the antibody is an antigen-binding fragment based on one or more identified antibody-encoding sequences.
- the antibody or antigen-binding fragments thereof lack an Fc domain.
- the antigen-binding portion thereof is incorporated into a bispecific antibody to combine other functionalities.
- the present invention provides for preparation of the antibody or antigen-binding molecule using any known platform, such as a single- domain antibody, a recombinant heavy-chain-only antibody (VHH), a single-chain antibody (scFv), a shark heavy-chain-only antibody (VNAR), a microprotein (cysteine knot protein, knottin), a DARPin; a Tetranectin; an Affibody; a Transbody; an Anticalin; an AdNectin; an Affilin; a Microbody; a peptide aptamer; an alterases; a plastic antibodies; a phylomer; a stradobodies; a maxibodies; an evibody; a fynomer, an armadillo repeat protein, a Kunitz domain, an avimer, an atrimer, a probody, an immunobody, a triomab, a troybody; a pepbody
- antibody fragments are prepared having the specificity of the full-length antibody comprising the identified sequences, but lacking effector functions (e.g., lacking Fc structures).
- the Fc region interacts with various cell surface receptors such as the Fc receptors and complement proteins thereby allowing the antibody to activate the immune system.
- administration of antibody fragments that lack the Fc structures e.g., Fab, Fab', F(ab3 ⁇ 4) or mutations that reduce or eliminate Fc receptor binding, provide targeted immune-suppressive effects to block immune processes involved in MS or other demyelinating or autoimmune disease.
- the antibody in various embodiments is a human recombinant antibody.
- Antibodies may be produced by standard methods well known in the art (see, e.g., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988; U.S. Patent 4,196,265).
- the VH4 antibodies can be prepared by co-transfection of cells with paired cloning vectors harboring IgK and IgH genes of the desired VH4 antibody.
- Recombinant antibodies can be harvested from transfected cell supernatants.
- DNA sequences encoding the antibodies or antigen-binding fragments thereof can be cloned or chemically synthesized using methods known in the art. Synthetic DNA sequences can be ligated to other appropriate nucleotide sequences, including, e.g. , expression control sequences, to produce gene expression constructs encoding the desired antibodies or antigen-binding fragments thereof.
- Nucleic acids encoding the antibodies or antigen-binding fragments thereof can be incorporated (ligated) into expression vectors, which can be introduced into host cells through transfection, transformation, or transduction techniques.
- nucleic acids encoding the antibodies or antigen-binding fragments thereof can be introduced into host cells by retroviral transduction.
- Illustrative host cells are E.coli cells, Chinese hamster ovary (CHO) cells, human embryonic kidney 293 (HEK 293) cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (e.g. , Hep G2), and myeloma cells.
- Transformed host cells can be grown under conditions that permit the host cells to express the genes that encode the antibodies or antigen-binding fragments thereof. Accordingly, in some embodiments, the present invention provides for a nucleic acid encoding an antibody or an antigen-binding fragment thereof. In some embodiments, the present invention provides expression vectors comprising nucleic acids that encode the antibodies or antigen-binding fragments thereof. In some embodiments, the present invention provides for a host cell comprising the nucleic acid encoding an antibody or an antigen- binding fragment thereof. In some embodiments, the present invention additional provides host cells comprising the expression vectors of the invention. Specific expression and purification conditions will vary depending upon the expression system employed. For example, if a gene is to be expressed in E.
- the engineered gene is first cloned into an expression vector by positioning the engineered gene downstream from a suitable bacterial promoter, e.g. , Trp or Tac, and a prokaryotic signal sequence.
- a suitable bacterial promoter e.g. , Trp or Tac
- a prokaryotic signal sequence e.g. , Trp or Tac
- the engineered gene is to be expressed in eukaryotic host cells, e.g. , CHO cells, it is first inserted into an expression vector containing for example, a suitable eukaryotic promoter, a secretion signal, enhancers, and various introns.
- the gene construct can be introduced into the host cells using transfection, transformation, or transduction techniques.
- the antibodies or antigen-binding fragments thereof can be produced by growing a host cell transfected with an expression vector encoding the antibodies or antigen-binding fragments thereof under conditions that permit expression of the protein. Following expression, the protein can be harvested and purified using techniques well known in the art, e.g. , affinity tags such as glutathione-S-transferase (GST) and histidine tags or by chromatography.
- affinity tags such as glutathione-S-transferase (GST) and histidine tags or by chromatography.
- Antibody fragments can be prepared by know processes, including a Fab, Fab', or F(ab') 2 fragments, for delivery to the patient.
- the present invention further provides pharmaceutical compositions that comprise an effective amount of the antibodies or antigen-binding fragments thereof or pharmaceutically-acceptable salt thereof, and a pharmaceutically - acceptable carrier or diluent. Methods for formulating such compositions are described previously.
- any pharmaceutical composition described herein is formulated in accordance with routine procedures as a composition adapted for a mode of administration described herein.
- any pharmaceutical composition described herein can take the form of solutions, suspensions, emulsion, drops, tablets, pills, pellets, capsules, capsules containing liquids, gelatin capsules, powders, sustained-release formulations, suppositories, emulsions, aerosols, sprays, suspensions, lyophilized powder, frozen suspension, desiccated powder, or any other form suitable for use.
- Exemplary routes of administration include, for example: oral, intradermal, intrathecal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, sublingual, intranasal, intracerebral, intravaginal, transdermal, rectally, by inhalation, or topically.
- Administration can be local or systemic. The mode of administration can be left to the discretion of the practitioner, and will depend in-part upon the site of the medical condition.
- the pharmaceutical composition is formulated for parenteral administration (e.g. intravenous, intramuscular, intraperitoneal, subcutaneous, intrathecal, and infusion).
- Formulations suitable for parenteral administration include, for example, solutions, suspensions, dispersions, emulsions, and the like. They may also be manufactured in the form of sterile solid compositions (e.g. lyophilized composition), which can be dissolved or suspended in sterile injectable medium immediately before use. They may contain, for example, suspending or dispersing agents known in the art.
- Formulation components suitable for parenteral administration include a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl paraben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as EDTA; buffers such as acetates, citrates or phosphates; and agents for the adjustment of tonicity such as sodium chloride or dextrose.
- Pharmaceutical formulations preferably are sterile. Sterilization can be accomplished, for example, by filtration through sterile filtration membranes. Where the composition is lyophilized, filter sterilization can be conducted prior to or following lyophilization and reconstitution.
- the present invention is used to treat MS.
- the therapeutic agents described herein e.g. , oligonucleotide-based or protein based therapeutic agents
- the therapeutic agents described herein are used to eliminate and reduce multiple MS symptoms.
- Illustrative symptoms associated with multiple sclerosis include: optic neuritis, diplopia, nystagmus, ocular dysmetria, intemuclear ophthalmoplegia, movement and sound phosphenes, afferent pupillary defect, paresis, monoparesis, paraparesis, hemiparesis, quadraparesis, plegia, paraplegia, hemiplegia, tetraplegia, quadraplegia, spasticity, dysarthria, muscle atrophy, spasms, cramps, hypotonia, clonus, myoclonus, myokymia, restless leg syndrome,
- the present methods are used to treat clinically isolated syndrome (CIS).
- a clinically isolated syndrome (CIS) is a single monosymptomatic attack compatible with MS, such as optic neuritis, brain stem symptoms, and partial myelitis.
- Patients with CIS that experience a second clinical attack are generally considered to have clinically definite multiple sclerosis (CDMS). Over 80 percent of patients with CIS and MRI lesions go on to develop MS, while approximately 20 percent have a self-limited process.
- Patients who experience a single clinical attack consistent with MS may have at least one lesion consistent with multiple sclerosis prior to the development of clinically definite multiple sclerosis.
- the present methods are used to treat CIS so it does not develop into MS.
- the present methods are used to treat radiologically isolated syndrome (RIS).
- RIS radiologically isolated syndrome
- incidental imaging findings suggest inflammatory demyelination in the absence of clinical signs or symptoms.
- the present methods are used to treat RIS so it does not develop into MS.
- the present oligonucleotide or protein-based agents are used to treat benign multiple sclerosis; relapsing-remitting multiple sclerosis (RRMS); secondary progressive multiple sclerosis (SPMS); progressive relapsing multiple sclerosis (PRMS); and primary progressive multiple sclerosis (PPMS).
- RRMS relapsing-remitting multiple sclerosis
- SPMS secondary progressive multiple sclerosis
- PRMS progressive relapsing multiple sclerosis
- PPMS primary progressive multiple sclerosis
- Benign multiple sclerosis is a retrospective diagnosis which is characterized by 1-2 exacerbations with complete recovery, no lasting disability and no disease progression for 10-15 years after the initial onset. Benign multiple sclerosis may, however, progress into other forms of multiple sclerosis. In various embodiments, the present methods are used to treat benign multiple sclerosis so it does not develop into MS.
- RRMS Patients suffering from RRMS experience sporadic exacerbations or relapses, as well as periods of remission. Lesions and evidence of axonal loss may or may not be visible on MRI for patients with RRMS.
- the present methods are used to treat RRMS.
- a clinical relapse which may also be used herein as "relapse,” “confirmed relapse,” or “clinically defined relapse,” is the appearance of one or more new neurological abnormalities or the reappearance of one or more previously observed neurological abnormalities.
- SPMS may evolve from RRMS. Patients afflicted with SPMS have relapses, a diminishing degree of recovery during remissions, less frequent remissions and more pronounced neurological deficits than RRMS patients.
- Enlarged ventricles which are markers for atrophy of the corpus callosum, midline center and spinal cord, are visible on MRI of patients with SPMS.
- the present methods are used to treat RRMS so it does not develop into SPMS
- PPMS is characterized by a steady progression of increasing neurological deficits without distinct attacks or remissions. Cerebral lesions, diffuse spinal cord damage and evidence of axonal loss are evident on the MRI of patients with PPMS. PPMS has periods of acute exacerbations while proceeding along a course of increasing neurological deficits without remissions. Lesions are evident on MRI of patients suffering from PRMS. In various embodiments, the present methods are used to treat RRMS and/or SPMS so it does not develop into PPMS.
- the present methods are used to treat relapsing forms of MS. In some embodiments, the present methods are used to treat relapsing forms of MS to slow the accumulation of physical disability and/or reduce the frequency of clinical exacerbations, and, optionally, for patients who have experienced a first clinical episode and have MRI features consistent with MS. In some embodiments, the present methods are used to treat worsening relapsing-remitting MS, progressive-relapsing MS or secondary-progressive MS to reduce neurologic disability and/or the frequency of clinical exacerbations. In some embodiments, the present methods can effectively reduce the frequency and/or severity of relapses.
- various clinical or other indicia of effectiveness of treatment may be used, e.g. , expanded disability status score (EDSS); MRI scan; relapse number, rate, or severity; multiple sclerosis functional composite (MSFC); multiple sclerosis quality of life inventory (MSQLI); Paced Serial Addition Test (PASAT); symbol digit modalities test (SDMT); 25-foot walk test; 9-hole peg test; low contrast visual acuity; Modified Fatigue Impact Scale; multiple sclerosis functional composite (MSFC); Beck Depression Inventory; and 7/24 Spatial Recall Test can be used.
- the present methods cause an improvement in one or more of these measures.
- the oligonucleotides, antibodies or antigen-binding fragments thereof, or pharmaceutical compositions are administered to a patient undergoing treatment with another therapeutic agent. In some embodiments, the oligonucleotides, antibodies or antigen-binding fragments thereof, or pharmaceutical compositions of the invention are administered to a patient before, during, or after treatment with another therapeutic agent. In some embodiments, the other therapeutic agent is part of a disease-modifying therapy for treating MS.
- MS disease- modifying therapeutic agents include, but are not limited to, one or more of teriflunomide (AUBAGIO (Genzyme)); interferon beta- la (AVONEX (Biogen poutier); interferon beta-lb (BETASERON (Bayer Healthcare Pharmaceuticals, Inc.); glatiramer acetate (COPAXONE (Teva Neuroscience); interferon beta-lb (EXTAVIA (Novartis Pharmaceuticals Corp.); fingolimod (GILENYA (Novartis Pharmaceuticals Corp.); alemtuzumab (LEMTRADA (Genzyme); mitoxantrone (NOVANTRONE (EMD Serono, Inc.); pegylated interferon beta- la (PLEGRIDY (BIOGEN IDEC); interferon beta-la (REBIF (EMD Serono, Inc.)); dimethyl fumarate (BG-12) (TECFIDERA (Biogen pou); and natalizumab (TYSABRI (Biogen
- the invention provides methods for producing therapeutic antibodies to target destruction of unwanted cells, including malignant cells and pathogens.
- B cells and corresponding antibodies are identified that can direct a productive or effective antibody response.
- evidence of inflammation i.e. lymphocyte infiltration
- B cells may be participating in this immune response by generating specific antibodies targeting the tumor for destruction.
- These antibodies targeting the tumor could be of either a particular heavy or light chain gene family, or carry particular mutations within their heavy or light chain genes.
- antibody genes isolated from single B cells identified within or near the tumor can be cloned and tested for their ability to bind to tumor antigens.
- Antibodies that bind to tumor antigens are binned separate from those that do not, and the antibody genetics of the two groups compared. For individual patients, this would provide an avenue for producing one or more of the specific antibodies ex vivo and giving it back to the patient as a therapeutic to more effectively target the tumor for destruction, or even use as an imaging enhancer. Further, the genetics of tumor binding antibodies for several patients with the same tumor type can be determined, with the hypothesis that there are particular heavy or light chain genes or particular mutations within the heavy and light chain genes of tumor-binding antibodies that are common to all (or many) patients with a particular tumor type. These antibodies could also be produced ex vivo and given to patients with this type of tumor, whether they make that particular antibody or not. Similar strategies can be effective for various infectious diseases, where antibodies that target pathogen or pathogen-associated molecules are needed.
- the invention provides a method for producing a therapeutic antibody.
- the method comprises providing a first population of B cells from one or more subjects displaying an immune response against a malignancy or infectious disease, and a second population of B cells that do not display said immune response.
- the presence of desired binding to target cells can be determined by standard immunochemistry methods.
- the method further comprises determining nucleotide sequences for immunoglobulin-encoding genes or transcripts in the populations, and identifying immunoglobulin-encoding sequences associated with the immune response (e.g., binding to target cells).
- the method further comprises producing antibodies or antigen- binding portions thereof encoded by one or more of the nucleotide sequences that are associated with the immune response. Antigen-binding affinity can be confirmed with the recombinantly produced antibodies.
- the B cells displaying an immune response are from a patient having a malignancy.
- malignancies include squamous or basal cell carcinoma, melanoma, biliary tract cancer, bladder cancer, bone cancer, brain or central nervous system cancer, breast cancer, cancer of the peritoneum, cervical cancer, colon or rectum cancer, cancer of the digestive system, endometrial cancer, esophageal cancer, eye cancer, cancer of the head and neck, gastric cancer, glioblastoma, neuroblastoma, liver cancer, kidney cancer, larynx cancer, leukemia, lung cancer, small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, mesothelioma, myeloma, oral cavity cancer, ovarian cancer, pancreatic cancer, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland carcinoma, testicular cancer, thyroid cancer, uterine cancer, lymphom
- the malignancy is a solid tumor.
- B cells are optionally isolated from tumor tissue or surrounding tissue, or in some embodiments are isolated from peripheral blood.
- the first population of B cells can be distinguished empirically from the second population of B cells by the affinity of the antibody produced for tumor cells or tumor antigens.
- the second population of B cells (the control population) can be from the same patient(s) as the first population, but isolated from non-tumor tissue, such as peripheral blood in some embodiments.
- the second population in some embodiments comprises B cells from patients who have a different tumor type or are non-cancerous, or in some embodiments are isolated from patients with the tumor type, but who are not mounting an effective antibody response.
- Antibody gene sequencing, evaluation of antibody genetics, and cloning can be conducted as discussed elsewhere herein in the context of autoimmune disease.
- the antibodies or antigen-binding portions thereof are recombinantly produced and administered to patients to target the tumor for destruction or as an imaging reagent (e.g., with conjugated detectable label).
- the subject has an infectious disease, which may be caused by a bacteria, virus, fungus, or parasite.
- B cells are isolated from infected tissue, or are isolated from peripheral blood or other suitable source.
- the first population of B cells can be distinguished from the second population of B cells by their affinity for pathogen cells or pathogen-associated antigens, and this process can employ automated techniques using immobilized antigen in some embodiments.
- the second population of B cells are from the same patient(s) as the first population, but are isolated from non-infected tissue or peripheral blood in some embodiments.
- the second population comprises B cells from patients that do not display a productive immune response against the same pathogen, or are isolated from patients testing positive for a different (but optionally related) pathogen or non-pathogenic microbe. In some embodiments, the second population are isolated from healthy controls.
- the antibodies or antigen-binding portions thereof are recombinantly produced and administered to one or more patients to target the pathogen.
- the pathogen may be a virus.
- viruses include retroviruses (e.g., HIV), herpes simplex viruses (e.g, HSV-1, HSV-2, or varicella zoster), hepatitis viruses (e.g., HAV, HBV, HCV), adenovirus, HPV, Epstein- Barr Virus (EBV), Ebola, Marburg virus, and zika virus.
- the infectious disease is a persistent or recurrent bacterial infection, such as that associated with pneumonia, bronchitis, sinusitis, vaginitis, enteritis, colitis, sepsis, or urinary tract infection.
- Exemplary bacterial pathogens for which the invention may be effective include species of Mycobacterium (including tuberculosis), Pseudomonas (e.g., Pseudomonas aeruginosa, as may occur in association with cystic fibrosis), Haemophilus (e.g., Haemophilus influenzae), Moraxella, Chlamydia, Neisseria, Streptococcus, Staphylococcus (including MRSA), Bordetella, Yersinia, and others.
- Mycobacterium including tuberculosis
- Pseudomonas e.g., Pseudomonas aeruginosa, as may occur in association with cystic fibrosis
- Haemophilus e.g., Haemophilus influenzae
- Moraxella Chlamydia, Neisseria, Streptococcus, Staphylococcus (including MRSA), Bordetell
- Exemplary fungal or parasitic infections include Candidiasis (e.g., yeast vaginitis), malaria, trypanosomiasis, Aspergillus infection, toxoplasma, and Giardiasis. Modifications of the disclosed embodiments incorporating the spirit and substance of the invention may occur to persons skilled in the art and such modifications are within the scope of the present invention.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Developmental Biology & Embryology (AREA)
- Pathology (AREA)
- Nanotechnology (AREA)
Abstract
The present invention relates to treatment of disease, including treatment of antibody-mediated autoimmune disorders, as well as treatment of other conditions in which antibody therapeutics can be beneficial for targeting destruction of foreign or malignant cells.
Description
TREATMENT OF DISEASE BASED ON IMMUNE CELL SEQUENCING
FIELD OF THE INVENTION
The present invention relates to treatment of disease, including treatment of antibody-mediated autoimmune disorders, as well as treatment of other conditions in which antibody therapeutics can be beneficial for targeting destruction of foreign or malignant cells.
SUMMARY OF THE INVENTION In certain aspects, the invention provides methods for treating antibody- mediated autoimmune disease, including demyelinatng diseases, as well as treatment of other conditions in which antibody therapeutics can be beneficial for targeting desctruction of foreign or malignant cells.
In various embodiments, the methods involve determining nucleotide sequences in a patient sample for a plurality of immunoglobulin-encoding genes or transcripts, and particularly the nucleotide sequences encoding at least a portion of the complementarity-determining regions (CDRs), which are representative of the antigen- binding specificity. By identifying nucleotide sequences that correspond to the disease, therapeutics can be designed or developed, including oligonucleotide or antibody therapeutics (e.g., to specifically target the patient's pathological antibody component).
For example, in some embodiments, the patient exhibits one or more symptoms of a neurodegenerative or demyelinating disorder, such as multiple sclerosis (MS), such as relapsing remitting MS (RRMS), secondary progressive MS (SPMS), primary progressive MS (PPMS), or progressive relapsing MS (PRMS). In some embodiments, the patient has clinically isolated syndrome (CIS), and is at risk of progressing to MS. In some embodiments, the patient has optic neuritis, neuromyelitis optica, or transverse myelitis. The invention can be applied to other autoimmune conditions as described herein.
In various embodiments, the methods involve determining an antibody repertoire of a patient, for example, by amplification and sequencing of antibody genes or transcripts from patient B cells. For example, antibody heavy chains (e.g., variable
heavy chain sequences) can be sequenced and used to identify pathological sequences, or in some embodiments, paired heavy and light chains are sequenced. In some embodiments, antibodies of interest are cloned and evaluated by immunochemistry with samples that comprise the autoantigen (e.g., tissue, cell sample, or purified or partially purified antigen), to confirm that antibodies of interest are likely involved in the autoimmune pathology.
In some embodiments, the patient has a demyelinating disease such as MS, and mutation at defined codons in VH4 antibodies are evaluated, to identify the presence, absence, or relative level of VH4 antibodies that are indicative of MS or other demyelinating disease or inflammatory disease of the CNS. For example, VH4 antibodies having mutations in least 2 codons selected from 3 IB, 32, 40, 56, 57, 60, 81, and 89 (which correspond to progression to MS) are selected as being potentially pathological antibodies for the patient's disease.
Once antibody-encoding nucleotide sequences that correspond to the patient's autoimmune disease have been identified in the patient's antibody repertoire, the invention involves designing a therapeutic agent to target the identified sequences. In various embodiments, from 1 to about 20, or from 1 to about 10, or from 1 to about 5 (e.g., 1, 2, 3, 4, or 5) antibody sequences are identified for targeting. For example, the therapeutic agent(s) may be antisense oligonucleotides or siRNAs specific for one or more the sequences identified. In other embodiments, the therapeutic agents include one or more antibodies or fragments thereof, modified to lack immune effector functions relevant to the disease processes (e.g., inflammation and/or demyelination). The oligonucleotides and antibodies may be formulated as a variety of pharmaceutical compositions, including for administration by a variety of routes. In other aspects, the invention provides methods for producing therapeutic antibodies to target destruction of unwanted cells, including malignant cells and pathogens. In these embodiments, B cells and corresponding antibodies are identified that can direct a productive or effective antibody response against the unwanted cells.
For example, in some embodiments a first population of B cells from one or more subjects displaying an immune response against a malignancy or infectious disease is provided, and the corresponding antibody genetics evaluated against
antibodies from a second population of B cells that do not exhibit the immune response of interest. The second population of B cells can be from the same subjects as the first population, or from different subjects. For example, B cells can be isolated from tumor tissue or infected tissue of patients exhibiting a productive immune response, and resulting antibody genetics evaluated against antibody sequences from other B cell populations. The antibodies or antigen-binding fragments or portions thereof identified as involved in the immune response of interest, are cloned, recombinantly produced, and formulated for administration to patients.
All references cited herein are hereby incorporated by reference in their entirety. Other aspects and embodiments of the present invention will be apparent from the following detailed description.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to treatment of disease, including treatment of antibody-mediated autoimmune disorders, as well as treatment of other conditions in which antibody therapeutics can be beneficial for targeting destruction of foreign or malignant cells.
In some aspects, to better inform and implement neuroprotective and neurodegenerative strategies, the present invention employs a biologically-directed approach to identify key pathophysiological antibody sequences and integrate them into a novel class of protein or oligonucleotide therapies. The present invention in various aspects provides therapy for demyelinating diseases, such as multiple sclerosis, without exposing the patient to the risk of a systemic immune cell ablation.
At present, there are no medications approved by the U. S. Food and Drug Administration (FDA) that provide neuroprotection in MS. The approved disease- modifying therapies work primarily by reducing inflammation in CNS, but are not well suited for a disease course that is characterized by nerve degeneration rather than inflammation. Preliminary results with Ocrelizumab suggest that B cell intervention can be a key strategy for the treatment of both RRMS and PPMS. However, Ocrelizumab destroys most of the B cells resident in a patient. Not surprisingly, this aggressive approach to disease intervention has clear limitations, as exhibited in earlier
clinical trials for the treatment of Lupus and Rheumatoid Arthritis where the drug had to be abandoned because of an unacceptable number of serious and sometimes fatal opportunistic infections. A more precise therapy targeted to the pathological B cell component could drastically improve therapy for MS disease and related demyelinating conditions.
In various aspects, the invention provides methods for treating autoimmune diseases, such as demyelinatng diseases. In the various embodiments, the methods involve determining nucleotide sequences in a patient sample for a plurality of immunoglobulin-encoding genes or transcripts, and particularly the nucleotide sequences encoding at least a portion of the complementarity-determining region (CDR), which are representative of the antigen-binding specificity. By identifying nucleotide sequences that correspond to the autoimmune disease, oligonucleotide or protein therapeutics can be designed to specifically target the patient's pathological antibody component. Exemplary antibody-mediated autoimmune diseases in which the invention finds use include multiple sclerosis, neuromyelitis optica, optic neuritis, transverse myelitis, acute disseminated encephalitis, systemic lupus erythematosus (SLE), rheumatoid arthritis, Sjogren's disease, psoriasis, vasculitis, Crohn's disease, and inflammatory bowel disease, among others. In some embodiments, the autoimmune disease is characterized by type II or type III hypersensitivity. In some embodiments, the autoimmune disease is a demyelinating disease.
In some embodiments, the patient exhibits one or more symptoms of a neurodegenerative or demyelinating disorder, such as multiple sclerosis (MS). In some embodiments, the patient may be diagnosed as having MS. MS is one of the most common diseases of the central nervous system (brain and spinal cord). It is an inflammatory condition associated with demyelination, or loss of the myelin sheath. Myelin, a fatty material that insulates nerves, acts as insulator in allowing nerves to transmit impulses from one point to another. In MS, the loss of myelin is accompanied by a disruption in the ability of the nerves to conduct electrical impulses to and from the brain and this produces the various symptoms of MS, such as impairments in vision, muscle coordination, strength, sensation, speech and swallowing, bladder control, sexuality and cognitive function. The plaques or lesions where myelin is lost
appear as hardened, scar-like areas. These scars appear at different times and in different areas of the brain and spinal cord. In some embodiments, the patient has relapsing remitting MS (RRMS), secondary progressive MS (SPMS), primary progressive MS (PPMS), or progressive relapsing MS (PRMS). In some embodiments, the patient has clinically isolated syndrome (CIS), and is at risk of progressing to MS. In some embodiments, the patient has optic neuritis, neuromyelitis optica, or transverse myelitis.
In various embodiments, the methods involve determining an antibody repertoire of a patient, for example, by amplification and sequencing of antibody genes or transcripts from patient B cells. Methods for determining an antibody repertoire by nucleotide sequencing have been described in US 2014/0371103 and US 2014/0357500, which are each hereby incorporated by reference in their entireties. Sequencing methods are generally in high-throughput, but can employ any sequencing platform including pyrosequencing, sequencing-by-synthesis, or nanopore sequencing platform, among others.
In various embodiments, antibody heavy chains or portions thereof preferably comprising one or more CDRs, can be sequenced and evaluated to identify pathological antibody sequences. In some embodiments, paired heavy and light chains are clonally amplified and sequenced. Sequencing can take place by any known sequencing process, including high throughput sequencing-by-synthesis or pyrosequencing. For example, without limitation, isolated immune cells can be encapsulated in water in oil emulsions to create individual picoliter compartments containing a single immune cell or less per droplet. Millions of cells can be processed for each patient allowing high throughput in single cell sequencing technology. Micron scale paramagnetic beads harboring oligonucleotides complementary to the VH and VL antibody chains are introduced during the emulsion process. These beads may carry long degenerate barcodes such that each bead can confer a unique identity code. The millions of single immune cells are lysed inside the emulsion and the antibody transcripts are reverse transcribed using the barcoded bead primers, followed by PCR amplification of the VH and VL chains. Each VH and VL chain stemming from a single immune cell can be virtually linked to each other with the same barcode identity.
The VH and VL chains are then recovered from the emulsion, and PCR enriched in order to add next-generation sequencing (NGS) tags. The library can be sequenced using a high throughput sequencing platform followed by analysis of repertoire diversity, antibody frequency, CDR3 characterization, somatic hypermutation phylogeny analysis, etc. A database of correctly matched VH and VL pairs can be generated by deconvoluting the bead barcode sequences. Because each single immune cells were isolated in their respective emulsion droplets, for each barcode observed twice, the transcripts sequenced originated from a same emulsion droplets and therefore from a unique single cell. In parallel to the sequencing, select VH and VL sequences of interest can be optionally cloned into antibody expression vectors and co-transfected and produced for characterization. For example, antibodies of interest can be evaluated by immunochemistry with a source of autoantigen, which can be a tissue, cell or cell line, or purified or partially purified antigen. For example, in the case of MS or demyelinating disease, the source of autoantigen can be brain or CNS samples, and staining patterns can be evaluated for staining of white and gray matter. This process can confirm that the antibody is likely involved in disease pathology. In some embodiments, in the case of MS or demyelinating disease, the selected antibody binds an antigen in human and/or mouse gray matter. In certain embodiments, antibody-producing immune cells can be isolated from the blood or other biological samples of the patient. In some embodiments, the lymphocyte pool can be enriched for the desired immune cells by any suitable method, such as screening and sorting the cells using fluorescence-activated cell sorting (FACS), magnetic activated cell sorting (MACS), panning or other screening method to generate a plurality of immune cells from a sample. In some embodiments, in the case of MS or demyelinating disease, B cells are recovered from a cerebrospinal fluid sample from the patient, or alternatively, the starting material is peripheral blood. The peripheral blood cells can be enriched for B cells or plasmablasts.
The germline VH genes are separated into at least six families (VH1 through VH6) based on DNA nucleotide sequence identity of the first 95 to 101 amino acids. Members of the same family typically have 80% or more sequence identity, whereas members of different families have less than 70% identity. These families range in size
from one VH6 gene to an estimated greater than 45 VH3 genes. For example, VH4 family genes, which are of interest for demyelinating diseases, contain 9 different members: 4-04, 4-28, 4-30, 4-31, 4-34, 4-39, 4-59, 4-61, 4-B.
Thus, in some embodiments, amplification of immune cell genetic material, e.g. reverse transcription polymerase chain reaction (RT-PCR), is employed to generate cDNA amplification of immune cell genetic material. For antibody molecules, the immunoglobulin genes can be obtained from genomic DNA or mRNA of immune cells. RNA can be heavy chain (V, D, J segments), or light chain (V, J segments), or portions thereof. In some embodiments, the starting material is RNA from immune cells composed of V, D, J gene segments.
While in some embodiments, the method amplifies and/or sequences IgG antibodies, one or more other isotypes can be sequenced alternatively or in addition, such as IgM, IgA, IgE and IgD isotypes, as well as antibody subtype. In the case of IgG, the sequencing can be specific for one or more of VHl, VH2, VH3, VH4, VH5, or VH6. In some embodiments, VH4 antibodies are sequenced, which are considered to play a role in the pathology of MS and related neurodegenerative diseases. Processes for sequencing VH4 sequences are disclosed in US 2014/0371103, which is hereby incorporated by reference.
In some embodiments, mutation at defined codons in VH4 antibodies are evaluated, to identify the presence, absence, or relative level of VH4 antibodies that are indicative of MS or other demyelinating disease or inflammatory disease of the CNS. For example, U. S. Patent No. 8,394,583 (the entire disclosure of which is hereby incorporated by reference) describes a biomarker for conversion from CIS to clinically definite MS (CDMS) in the antibody genetics of Vn4-utilizing B cells. Antibodies having mutations in least 2 codons selected from 31B, 32, 40, 56, 57, 60, 81, and 89 (which correspond to progression to MS) are selected as being potentially pathological antibodies for the patient's disease. Codon positions are defined by Kabat numbering, and mutations are identified with respect to the germline sequence. VH4 genes or transcripts can include one or more (or all) subfamily genes, for example, 4-04, 4-28, 4- 30, 4-31, 4-34, 4-39, 4-59, 4-61, and 4-B.
Further, VH4 signatures indicative of neuromyelitis optica (NMO) are described in WO 2013/059417, the entire contents of which are hereby incorporated by reference.
While it is not necessary to evaluate particular amino acid identities in various embodiments, exemplary substitutions at these codons are disclosed in WO 2015/070009, the entire disclosure of which is hereby incorporated by reference.
In various embodiments, signature VH4 sequences generally comprise two or more mutations at codon positions 3 IB, 32, 40, 56, 57, 60, 81, and 89. In various embodiments, the VH4 antibody comprises at least 3, or at least 4, or at least 5, or at least 6 mutations with respect to the germline sequence at these positions. In some embodiments, the VH4 antibody comprises mutations at one or more of codons 32, 40, 57, 60, and 89 with respect to the germline sequence. In some embodiments, the VH4 antibody comprises mutations at two or more of codons 56, 57, and 81 with respect to the germline sequence. In some embodiments, the VH4 antibody comprises mutations at two or more of codons 40, 56, 81, and 89 with respect to the germline sequence.
Various antibody clones that harbor the VH4 signature, and their immunohistochemistry staining patterns of brain tissue are disclosed in WO 2015/070009, which is hereby incorporated by reference in its entirety. For example, exemplary mutations at codon 3 IB include R, N, D, P, K, G, A, and T; exemplary mutations at codon 40 include S, L, and A; exemplary mutations at codon 56 include R, G, N, T, Y, H, D, and K; exemplary mutation at codon 57 include A, I, D, and S; exemplary mutations at codon 81 include N, R, and M; exemplary mutations at codon 89 include F, I, R, and L. The methods are however not limited to these mutations or sets of mutations described in WO 2015/070009. Other antibody signatures that are indicative of other conditions can be identified by sequencing the antibody repertoire of a suitable patient cohort or isolated B cell population of interest, and comparing the sequences to a control B cell population. The control B cell population does not exhibit the reactivity of interest, and in various embodiments may be isolated from healthy controls, or controls that include other inflammatory or degenerative diseases, or from locations of the body not affected by the disease of interest. For example, antibody gene signatures can be identified
using known classifier algorithms including, without limitation: Principal Components Analysis, Naive Bayes, Support Vector Machines, Nearest Neighbors, Decision Trees, Logistic, Artificial Neural Networks, Penalized Logistic Regression, and Rule-based schemes. In addition, the predictions from multiple models can be combined to generate an overall prediction. The process for preparing a suitable class predictor is reviewed in R. Simon, Diagnostic and prognostic prediction using gene expression profiles in high-dimensional microarrav data. British Journal of Cancer (2003) 89, 1599-1604, which review is hereby incorporated by reference in its entirety.
Antibody signatures can include mutational frequency at select codons (usually in CDR regions of heavy and/or light chains), identity and/or frequency of amino acid substitutions (e.g., including analysis of conserved or non-conserved substitutions), antibody isotype, and V-D-J gene usage, for example.
Once signature nucleotide sequences that correspond to the autoimmune disease have been identified in the patient's antibody repertoire, the invention involves designing a therapeutic agent to target the identified antibody sequences. In various embodiments, from 1 to about 20, or from 1 to about 10, or from 1 to about 5 (e.g., 1, 2, 3, 4, or 5) sequences are identified for targeting. For example, the therapeutic agent may be one or more antisense oligonucleotides or siRNAs specific for one or more the sequences identified. In other embodiments, the therapeutic agent is a recombinant antibody or antigen-binding fragment or portion thereof.
Antisense oligonucleotides are typically in the range of 8 to 30 nucleotides in length, and 12 to 25 nucleotides in some embodiments, although the invention is not strictly tied to any particular size. Specifically, oligonucleotides can be designed that are complementary to the variable heavy or variable light sequences in regions harboring the antibody gene signature. For example, the oligonucleotide can be complementary to an antibody transcript in a region containing at least two codon mutations that are indicative of the disease. In some embodiments, the oligonucleotide is complementary to an antibody transcript in a region containing at least three or at least four codon mutations that are indicative of the disease. In some embodiments, antibody-encoding transcripts are identified that have at least 2, 3, or 4 mutations in the variable region that are indicative of disease, and which are within 20 nucleotides. For example, in some embodiments, a VH4 region of no more than about 25 or about 20
nucleotides, and within codons 3 IB to 89 of VH4, is identified that contains 2, 3, 4, or 5 (or more) signature mutations. These antibody-encoding transcripts are particularly suitable for antisense therapeutics. Oligonucleotide sequences are further identified that exhibit an appropriate Tm for therapeutic application, which can be further adjusted by nucleotide modifications are further described below.
In some embodiments, the same transcript is targeted by at least two antisense oligonucleotides, to thereby target additional regions harboring the antibody gene signature.
In some embodiments, siRNA(s) are designed to inhibit expression of the identified gene sequences. Structure, formulation, and delivery of siRNAs are described, for example, in US 2014/0161894, US 2014/0024699, US 2015/0197746, and US 2016/0076040, which are hereby incorporated by reference in their entireties. See also, Fakhr E. et al, Precise and efficient siRNA design: a key point in competent gene silencing. Cancer Gene Ther. 2016 Apr;23(4):73-82. Generally, design of siRNAs includes analysis of factors such as distance of target region to transcription start site, nucleotide composition, potential for off-target effects, secondary structures in the target site and siRNA, and the presence of asymmetry and energy valley within the siRNA.
Other methods and algorithms for designing oligonucleotides such as antisense oligonucleotides or siRNAs are known in the art. For example, modeling programs such as Foldsplit may be used to design antisense oligonucleotides (see Sczakiel G., et al (1993) Computer-aided search for effective antisense RNA target sequences of the human immunodeficiency virus type 1. Antisense Res. Dev. 3, 45-52). Algorithms for designing siRNAs are also known and include, without limitation, the Whitehead siRNA Selection Web Server (http://jura.wi.mit.edu/bioc/siRNA) as well as others described in Boese Q. et al, (2005) Mechanistic insights aid computational short interfering RNA design. Methods Enzvmol. 392:73-96.
Oligonucleotide therapeutics may contain one or more chemical modifications to impart stability and/or increase affinity for the target site, among other advantages. Exemplary chemical modifications include backbone modifications (e.g., phosphorothioate or phosphorodiamidate morpholino), as well as 2' modifications (e.g.,
2' O-methyl or 2' halo) and bridging modifications (e.g., locked nucleic acid, or other 2' to 4' bridge structure), base modifications, and/or cap structures. Exemplary modifications are described in US Patent 9, 163,235, US Patent 8,642,751 , and WO 2012/061810, which are hereby incorporated by reference in their entireties. The oligonucleotides may include at least one locked nucleotide (LNA), as described, for example, in U. S. Patent Nos. 6,268,490, 6,316, 198, 6,403,566, 6,770,748, 6,998,484, 6,670,461, and 7,034, 133, all of which are hereby incorporated by reference in their entireties.
In certain embodiments, the oligonucleotide further comprises at least one terminal modification or "cap". The cap may be a 5' and/or a 3 '-cap structure. The terms "cap" or "end-cap" include chemical modifications at either terminus of the oligonucleotide (with respect to terminal ribonucleotides), and including modifications at the linkage between the last two nucleotides on the 5' end and the last two nucleotides on the 3' end. The cap structure may increase resistance of the oligonucleotide to exonucleases without compromising molecular interactions with the RNA target. Such modifications may be selected on the basis of their increased potency in vitro or in vivo. The cap can be present at the 5'-terminus (5'-cap) or at the 3'-terminus (3'-cap) or can be present on both ends. In certain embodiments, the 5'- and/or 3 '-cap is independently selected from phosphorothioate monophosphate, abasic residue (moiety), phosphorothioate linkage, 4'-thio nucleotide, carbocyclic nucleotide, phosphorodithioate linkage, inverted nucleotide or inverted abasic moiety (2'-3' or 3 '- 3'), phosphorodithioate monophosphate, and methylphosphonate moiety.
The oligonucleotide may contain one or more phosphorothioate linkages. Phosphorothioate linkages have been used to render oligonucleotides more resistant to nuclease cleavage. For example, the polynucleotide may be partially phosphorothioate- linked, for example, phosphorothioate linkages may alternate with phosphodiester linkages. In certain embodiments, however, the oligonucleotide is fully phosphorothioate-linked. In other embodiments, the oligonucleotide has from one to five or one to three phosphate linkages. In a further embodiment, the oligonucleotide may include one or more morpholino nucleotides. In another embodiment, the oligonucleotide may include one
or more peptide nucleic acids (PNAs), which contain a peptide-based backbone rather than a sugar-phosphate backbone.
The oligonucleotides may be produced by a variety of techniques known in the art. For example, the synthesis of oligonucleotides, including modified polynucleotides, by solid phase synthesis is well known and is reviewed by Caruthers et al, New Chemical Methods for Synthesizing Polynucleotides. Nucleic Acids Symp. Ser., (7):215-23 (1980) which is hereby incorporated by reference in its entirety. The oligonucleotides, for example, siRNA, may also be synthesized by in vitro transcription (e.g., T7, T3 and/or SP6 RNA polymerase transcription with or without processing by ribonucleases such as Tl ribonuclease, or processing by phosphatases) or recombinant human Dicer/i?. coli RNaselll digestion of long double-stranded RNA molecules.
The oligonucleotide may be incorporated within a variety of macromolecular assemblies or compositions. Such complexes for delivery may include a variety of liposomes, nanoparticles, and micelles, formulated for delivery to a patient. In some embodiments, the oligonucleotides are incorporated within nanoparticles. For example, the oligonucleotides may be complexed with lipids thus forming lipid nanoparticles (LNPs). In another embodiment, the oligonucleotides may be complexed with polymeric nanocarriers to form polymeric nanoparticles. Polymeric nanoparticles may be formed from PLA or PLGA, PLA-PEG, PLGA-PEG, or combinations thereof. In various embodiments, the complexes may include one or more fusogenic or lipophilic molecules to initiate cellular membrane penetration. Such molecules are described, for example, in U. S. Patent No. 7,404,969 and U. S. Patent No. 7,202,227, which are hereby incorporated by reference in their entireties. Alternatively, the oligonucleotide may further comprise a pendant lipophilic group to aid cellular delivery, such as those described in WO 2010/129672, which is hereby incorporated by reference. In various embodiments, the oligonucleotides are conjugated to peptides, antibodies, polymers, ligands, and/or aptamers for targeted delivery. For example, the oligonucleotides may be conjugated to positively charged polymers. Examples of positively charged polymers include peptides, such as arginine rich peptides or TAT sequence. Another example of positively charged polymers is polyethylenimine (PEI) with multiple positively charged amine groups in its branched or unbranched chains.
In an embodiment, the oligonucleotides or complexes comprising the same are targeted for delivery to B cells. For example, the oligonucleotides may be associated with a B-cell targeting ligand. In another example, the oligonucleotides or complexes comprising the same may be associated with an antibody that recognizes a B-cell marker such as CD10, CD19, CD20, CD21, CD22, CD23, CD24, CD37, CD38, CD39, CD40, CD70, CD72, CD73, CD74, CDw75, CDw76, CD77, CD78, CD79a/b, CD80, CD81, CD82, CD83, CD84, CD85, CD86, CD89, CD98, CD126, CD127, CDwl30, CD138, or CDwl50.
The pharmaceutical compositions comprising an effective amount of the oligonucleotide(s) further comprise a pharmaceutically-acceptable carrier or diluent. The composition or formulation may employ a plurality of therapeutic oligonucleotides, including at least one described herein. For example, the composition or formulation may employ at least about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, or about 10 oligonucleotides according to the present disclosure. In some embodiments, the compositions may include one or more oligonucleotides targeting the signature VH4 sequences unique to a patient.
The oligonucleotides of the invention may be formulated as a variety of pharmaceutical compositions. Pharmaceutical compositions will be prepared in a form appropriate for the intended application. Generally, this entails preparing compositions that are essentially free of pyrogens, as well as other impurities that could be harmful to humans or animals. Exemplary delivery/formulation systems include colloidal dispersion systems, macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. Commercially available fat emulsions that are suitable for delivering the nucleic acids of the invention include Intralipid®, Liposyn®, Liposyn® II, Liposyn® III, Nutrilipid, and other similar lipid emulsions. An exemplary colloidal system for use as a delivery vehicle in vivo is a liposome (i.e., an artificial membrane vesicle). The preparation and use of such systems is well known in the art. Exemplary formulations are also disclosed in U.S. Patent No. 5,981,505; U. S. Patent No. 6,217,900; U.S. Patent No. 6,383,512; U.S. Patent No. 5,783,565; U. S. Patent No. 7,202,227; U.S. Patent No. 6,379,965; U.S. Patent No. 6,127,170; U. S. Patent No.
5,837,533; U. S. Patent No. 6,747,014; and WO 2003/093449, which are hereby incorporated by reference in their entireties.
The pharmaceutical compositions and formulations may employ appropriate salts and buffers to render delivery vehicles stable and allow for uptake by target cells. Aqueous compositions comprise an effective amount of the delivery vehicle comprising the oligonucleotide (e.g. liposomes or other complexes), dissolved or dispersed in a pharmaceutically acceptable carrier or aqueous medium. As used herein, "pharmaceutically acceptable carrier" may include one or more solvents, buffers, solutions, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like acceptable for use in formulating pharmaceuticals, such as pharmaceuticals suitable for administration to humans. The use of such media and agents for pharmaceutically active substances is well known in the art. Supplementary active ingredients also can be incorporated into the compositions. In various embodiments, the present invention further relates to synthesizing one or more antibodies or antigen-binding fragments thereof encoded by identified antibody sequences indicative of the patient's disease. In some embodiments, the antibodies are VH4 antibodies. In some embodiments, the antibodies or antigen- binding fragments are cloned from the identified sequences, and expressed and recovered from a cell culture system. The antibodies, generaly lacking a functional Fc, are delivered to a patient to reduce or eliminate symptoms of the autoimmune or demyelinating disease, for example, by blocking the interaction of the endogenous autoantibodies with target tissue. Alternatively, or in addition, the present invention provides antibodies or anti-binding fragments thereof that bind to and neutralize the autoantibodies comprising the signature antibody sequences, thereby reducing or eliminating symptoms of the autoimmune disease.
In various embodiments, one or more antibody fragment or antigen-binding molecules are prepared against the identified antibodies. Each heavy chain includes one variable region (e.g., VH) and at least three constant regions (e.g., CHI, CH2 and CH3), and each light chain includes one variable region (VL) and one constant region (CL). The variable regions determine the specificity of the antibody. Each variable region comprises three hypervariable regions also known as complementarity
determining regions (CDRs) flanked by four relatively conserved framework regions (FRs). The three CDRs, referred to as CDR1, CDR2, and CDR3, contribute to the antibody binding specificity. In some embodiments, the antibody is an antigen-binding fragment based on one or more identified antibody-encoding sequences. In an embodiment, the antibody or antigen-binding fragments thereof lack an Fc domain. In some embodiments, the antigen-binding portion thereof is incorporated into a bispecific antibody to combine other functionalities.
In some embodiments, the present invention provides for preparation of the antibody or antigen-binding molecule using any known platform, such as a single- domain antibody, a recombinant heavy-chain-only antibody (VHH), a single-chain antibody (scFv), a shark heavy-chain-only antibody (VNAR), a microprotein (cysteine knot protein, knottin), a DARPin; a Tetranectin; an Affibody; a Transbody; an Anticalin; an AdNectin; an Affilin; a Microbody; a peptide aptamer; an alterases; a plastic antibodies; a phylomer; a stradobodies; a maxibodies; an evibody; a fynomer, an armadillo repeat protein, a Kunitz domain, an avimer, an atrimer, a probody, an immunobody, a triomab, a troybody; a pepbody; a vaccibody, a UniBody; affimers, a DuoBody, a Fv, a Fab, a Fab', a F(ab')2, a peptide mimetic molecule, or a synthetic molecule, as described in US Patent Nos. or Patent Publication Nos. US 7,417,130, US 2004/132094, US 5,831,012, US 2004/023334, US 7,250,297, US 6,818,418, US 2004/209243, US 7,838,629, US 7,186,524, US 6,004,746, US 5,475,096, US 2004/146938, US 2004/157209, US 6,994,982, US 6,794, 144, US 2010/239633, US 7,803,907, US 2010/119446, and/or US 7,166,697, the contents of which are hereby incorporated by reference in their entireties. See also, Storz MAbs. 2011 May-Jun; 3(3): 310-317. In some embodiments, antibody fragments are prepared having the specificity of the full-length antibody comprising the identified sequences, but lacking effector functions (e.g., lacking Fc structures). The Fc region interacts with various cell surface receptors such as the Fc receptors and complement proteins thereby allowing the antibody to activate the immune system. Without wishing to be bound by theory, it is believed that administration of antibody fragments that lack the Fc structures (e.g., Fab, Fab', F(ab¾) or mutations that reduce or eliminate Fc receptor binding, provide
targeted immune-suppressive effects to block immune processes involved in MS or other demyelinating or autoimmune disease.
The antibody in various embodiments is a human recombinant antibody. Antibodies may be produced by standard methods well known in the art (see, e.g., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988; U.S. Patent 4,196,265). For example, the VH4 antibodies can be prepared by co-transfection of cells with paired cloning vectors harboring IgK and IgH genes of the desired VH4 antibody. Recombinant antibodies can be harvested from transfected cell supernatants.
Methods for producing the antibodies or antigen-binding fragments thereof are known in the art. For example, DNA sequences encoding the antibodies or antigen- binding fragments thereof can be cloned or chemically synthesized using methods known in the art. Synthetic DNA sequences can be ligated to other appropriate nucleotide sequences, including, e.g. , expression control sequences, to produce gene expression constructs encoding the desired antibodies or antigen-binding fragments thereof.
Nucleic acids encoding the antibodies or antigen-binding fragments thereof can be incorporated (ligated) into expression vectors, which can be introduced into host cells through transfection, transformation, or transduction techniques. For example, nucleic acids encoding the antibodies or antigen-binding fragments thereof can be introduced into host cells by retroviral transduction. Illustrative host cells are E.coli cells, Chinese hamster ovary (CHO) cells, human embryonic kidney 293 (HEK 293) cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (e.g. , Hep G2), and myeloma cells. Transformed host cells can be grown under conditions that permit the host cells to express the genes that encode the antibodies or antigen-binding fragments thereof. Accordingly, in some embodiments, the present invention provides for a nucleic acid encoding an antibody or an antigen-binding fragment thereof. In some embodiments, the present invention provides expression vectors comprising nucleic acids that encode the antibodies or antigen-binding fragments thereof. In some embodiments, the present invention provides for a host cell comprising the nucleic acid encoding an antibody or an antigen- binding fragment thereof. In some embodiments, the present invention additional provides host cells comprising the expression vectors of the invention.
Specific expression and purification conditions will vary depending upon the expression system employed. For example, if a gene is to be expressed in E. coli, it is first cloned into an expression vector by positioning the engineered gene downstream from a suitable bacterial promoter, e.g. , Trp or Tac, and a prokaryotic signal sequence. In another example, if the engineered gene is to be expressed in eukaryotic host cells, e.g. , CHO cells, it is first inserted into an expression vector containing for example, a suitable eukaryotic promoter, a secretion signal, enhancers, and various introns. The gene construct can be introduced into the host cells using transfection, transformation, or transduction techniques. The antibodies or antigen-binding fragments thereof can be produced by growing a host cell transfected with an expression vector encoding the antibodies or antigen-binding fragments thereof under conditions that permit expression of the protein. Following expression, the protein can be harvested and purified using techniques well known in the art, e.g. , affinity tags such as glutathione-S-transferase (GST) and histidine tags or by chromatography. Antibody fragments can be prepared by know processes, including a Fab, Fab', or F(ab')2 fragments, for delivery to the patient.
Accordingly, the present invention further provides pharmaceutical compositions that comprise an effective amount of the antibodies or antigen-binding fragments thereof or pharmaceutically-acceptable salt thereof, and a pharmaceutically - acceptable carrier or diluent. Methods for formulating such compositions are described previously.
In various embodiments, any pharmaceutical composition described herein is formulated in accordance with routine procedures as a composition adapted for a mode of administration described herein. For example, any pharmaceutical composition described herein can take the form of solutions, suspensions, emulsion, drops, tablets, pills, pellets, capsules, capsules containing liquids, gelatin capsules, powders, sustained-release formulations, suppositories, emulsions, aerosols, sprays, suspensions, lyophilized powder, frozen suspension, desiccated powder, or any other form suitable for use.
Exemplary routes of administration include, for example: oral, intradermal, intrathecal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, sublingual, intranasal, intracerebral, intravaginal, transdermal, rectally, by inhalation, or topically. Administration can be local or systemic. The mode of administration can be left to the discretion of the practitioner, and will depend in-part upon the site of the medical condition. In some embodiments, the pharmaceutical composition is formulated for parenteral administration (e.g. intravenous, intramuscular, intraperitoneal, subcutaneous, intrathecal, and infusion).
Formulations suitable for parenteral administration include, for example, solutions, suspensions, dispersions, emulsions, and the like. They may also be manufactured in the form of sterile solid compositions (e.g. lyophilized composition), which can be dissolved or suspended in sterile injectable medium immediately before use. They may contain, for example, suspending or dispersing agents known in the art. Formulation components suitable for parenteral administration include a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl paraben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as EDTA; buffers such as acetates, citrates or phosphates; and agents for the adjustment of tonicity such as sodium chloride or dextrose. Pharmaceutical formulations preferably are sterile. Sterilization can be accomplished, for example, by filtration through sterile filtration membranes. Where the composition is lyophilized, filter sterilization can be conducted prior to or following lyophilization and reconstitution.
In various embodiments, the present invention is used to treat MS. In various embodiments, the therapeutic agents described herein (e.g. , oligonucleotide-based or protein based therapeutic agents) are used to eliminate and reduce multiple MS symptoms. Illustrative symptoms associated with multiple sclerosis, which can be potentially ameliorated or prevented with the compositions and methods described herein, include: optic neuritis, diplopia, nystagmus, ocular dysmetria, intemuclear ophthalmoplegia, movement and sound phosphenes, afferent pupillary defect, paresis, monoparesis, paraparesis, hemiparesis, quadraparesis, plegia, paraplegia, hemiplegia, tetraplegia, quadraplegia, spasticity, dysarthria, muscle atrophy, spasms, cramps,
hypotonia, clonus, myoclonus, myokymia, restless leg syndrome, footdrop, dysfunctional reflexes, paresthesia, anesthesia, neuralgia, neuropathic and neurogenic pain, Lhermitte's sign, proprioceptive dysfunction, trigeminal neuralgia, ataxia, intention tremor, dysmetria, vestibular ataxia, vertigo, speech ataxia, dystonia, dysdiadochokinesia, frequent micturation, bladder spasticity, flaccid bladder, detrusor- sphincter dyssynergia, erectile dysfunction, anorgasmy, frigidity, constipation, fecal urgency, fecal incontinence, depression, cognitive dysfunction, dementia, mood swings, emotional lability, euphoria, bipolar syndrome, anxiety, aphasia, dysphasia, fatigue, Uhthoff s symptom, gastroesophageal reflux, and sleeping disorders. In various embodiments, the present methods are used to treat clinically isolated syndrome (CIS). A clinically isolated syndrome (CIS) is a single monosymptomatic attack compatible with MS, such as optic neuritis, brain stem symptoms, and partial myelitis. Patients with CIS that experience a second clinical attack are generally considered to have clinically definite multiple sclerosis (CDMS). Over 80 percent of patients with CIS and MRI lesions go on to develop MS, while approximately 20 percent have a self-limited process. Patients who experience a single clinical attack consistent with MS may have at least one lesion consistent with multiple sclerosis prior to the development of clinically definite multiple sclerosis. In various embodiments, the present methods are used to treat CIS so it does not develop into MS. In various embodiments, the present methods are used to treat radiologically isolated syndrome (RIS). In RIS, incidental imaging findings suggest inflammatory demyelination in the absence of clinical signs or symptoms. In various embodiments, the present methods are used to treat RIS so it does not develop into MS.
In various embodiments, the present oligonucleotide or protein-based agents are used to treat benign multiple sclerosis; relapsing-remitting multiple sclerosis (RRMS); secondary progressive multiple sclerosis (SPMS); progressive relapsing multiple sclerosis (PRMS); and primary progressive multiple sclerosis (PPMS).
Benign multiple sclerosis is a retrospective diagnosis which is characterized by 1-2 exacerbations with complete recovery, no lasting disability and no disease progression for 10-15 years after the initial onset. Benign multiple sclerosis may, however, progress into other forms of multiple sclerosis. In various embodiments, the
present methods are used to treat benign multiple sclerosis so it does not develop into MS.
Patients suffering from RRMS experience sporadic exacerbations or relapses, as well as periods of remission. Lesions and evidence of axonal loss may or may not be visible on MRI for patients with RRMS. In various embodiments, the present methods are used to treat RRMS. A clinical relapse, which may also be used herein as "relapse," "confirmed relapse," or "clinically defined relapse," is the appearance of one or more new neurological abnormalities or the reappearance of one or more previously observed neurological abnormalities. SPMS may evolve from RRMS. Patients afflicted with SPMS have relapses, a diminishing degree of recovery during remissions, less frequent remissions and more pronounced neurological deficits than RRMS patients. Enlarged ventricles, which are markers for atrophy of the corpus callosum, midline center and spinal cord, are visible on MRI of patients with SPMS. In various embodiments, the present methods are used to treat RRMS so it does not develop into SPMS.
PPMS is characterized by a steady progression of increasing neurological deficits without distinct attacks or remissions. Cerebral lesions, diffuse spinal cord damage and evidence of axonal loss are evident on the MRI of patients with PPMS. PPMS has periods of acute exacerbations while proceeding along a course of increasing neurological deficits without remissions. Lesions are evident on MRI of patients suffering from PRMS. In various embodiments, the present methods are used to treat RRMS and/or SPMS so it does not develop into PPMS.
In some embodiments, the present methods are used to treat relapsing forms of MS. In some embodiments, the present methods are used to treat relapsing forms of MS to slow the accumulation of physical disability and/or reduce the frequency of clinical exacerbations, and, optionally, for patients who have experienced a first clinical episode and have MRI features consistent with MS. In some embodiments, the present methods are used to treat worsening relapsing-remitting MS, progressive-relapsing MS or secondary-progressive MS to reduce neurologic disability and/or the frequency of clinical exacerbations. In some embodiments, the present methods can effectively reduce the frequency and/or severity of relapses.
In some embodiments, various clinical or other indicia of effectiveness of treatment may be used, e.g. , expanded disability status score (EDSS); MRI scan; relapse number, rate, or severity; multiple sclerosis functional composite (MSFC); multiple sclerosis quality of life inventory (MSQLI); Paced Serial Addition Test (PASAT); symbol digit modalities test (SDMT); 25-foot walk test; 9-hole peg test; low contrast visual acuity; Modified Fatigue Impact Scale; multiple sclerosis functional composite (MSFC); Beck Depression Inventory; and 7/24 Spatial Recall Test can be used. In some embodiments, the present methods cause an improvement in one or more of these measures. In some embodiments, the oligonucleotides, antibodies or antigen-binding fragments thereof, or pharmaceutical compositions are administered to a patient undergoing treatment with another therapeutic agent. In some embodiments, the oligonucleotides, antibodies or antigen-binding fragments thereof, or pharmaceutical compositions of the invention are administered to a patient before, during, or after treatment with another therapeutic agent. In some embodiments, the other therapeutic agent is part of a disease-modifying therapy for treating MS. Exemplary MS disease- modifying therapeutic agents include, but are not limited to, one or more of teriflunomide (AUBAGIO (Genzyme)); interferon beta- la (AVONEX (Biogen Idee); interferon beta-lb (BETASERON (Bayer Healthcare Pharmaceuticals, Inc.); glatiramer acetate (COPAXONE (Teva Neuroscience); interferon beta-lb (EXTAVIA (Novartis Pharmaceuticals Corp.); fingolimod (GILENYA (Novartis Pharmaceuticals Corp.); alemtuzumab (LEMTRADA (Genzyme); mitoxantrone (NOVANTRONE (EMD Serono, Inc.); pegylated interferon beta- la (PLEGRIDY (BIOGEN IDEC); interferon beta-la (REBIF (EMD Serono, Inc.)); dimethyl fumarate (BG-12) (TECFIDERA (Biogen Idee); and natalizumab (TYSABRI (Biogen Idee).
In other aspects, the invention provides methods for producing therapeutic antibodies to target destruction of unwanted cells, including malignant cells and pathogens. In these embodiments, B cells and corresponding antibodies are identified that can direct a productive or effective antibody response. For example, in some cases of solid tumors, evidence of inflammation (i.e. lymphocyte infiltration) within or near the tumor is predictive of a positive immune response. B cells may be participating in this immune response by generating specific
antibodies targeting the tumor for destruction. These antibodies targeting the tumor could be of either a particular heavy or light chain gene family, or carry particular mutations within their heavy or light chain genes. Thus, antibody genes isolated from single B cells identified within or near the tumor can be cloned and tested for their ability to bind to tumor antigens. Antibodies that bind to tumor antigens are binned separate from those that do not, and the antibody genetics of the two groups compared. For individual patients, this would provide an avenue for producing one or more of the specific antibodies ex vivo and giving it back to the patient as a therapeutic to more effectively target the tumor for destruction, or even use as an imaging enhancer. Further, the genetics of tumor binding antibodies for several patients with the same tumor type can be determined, with the hypothesis that there are particular heavy or light chain genes or particular mutations within the heavy and light chain genes of tumor-binding antibodies that are common to all (or many) patients with a particular tumor type. These antibodies could also be produced ex vivo and given to patients with this type of tumor, whether they make that particular antibody or not. Similar strategies can be effective for various infectious diseases, where antibodies that target pathogen or pathogen-associated molecules are needed.
Thus, in some embodiments, the invention provides a method for producing a therapeutic antibody. The method comprises providing a first population of B cells from one or more subjects displaying an immune response against a malignancy or infectious disease, and a second population of B cells that do not display said immune response. The presence of desired binding to target cells (e.g., displayed by the first population, but not the second), can be determined by standard immunochemistry methods. The method further comprises determining nucleotide sequences for immunoglobulin-encoding genes or transcripts in the populations, and identifying immunoglobulin-encoding sequences associated with the immune response (e.g., binding to target cells). The method further comprises producing antibodies or antigen- binding portions thereof encoded by one or more of the nucleotide sequences that are associated with the immune response. Antigen-binding affinity can be confirmed with the recombinantly produced antibodies.
In some embodiments, the B cells displaying an immune response are from a patient having a malignancy. Exemplary malignancies include squamous or basal cell
carcinoma, melanoma, biliary tract cancer, bladder cancer, bone cancer, brain or central nervous system cancer, breast cancer, cancer of the peritoneum, cervical cancer, colon or rectum cancer, cancer of the digestive system, endometrial cancer, esophageal cancer, eye cancer, cancer of the head and neck, gastric cancer, glioblastoma, neuroblastoma, liver cancer, kidney cancer, larynx cancer, leukemia, lung cancer, small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, mesothelioma, myeloma, oral cavity cancer, ovarian cancer, pancreatic cancer, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland carcinoma, testicular cancer, thyroid cancer, uterine cancer, lymphoma, Hodgkin's lymphoma, non- Hodgkin's lymphoma, Cutaneous T-Cell Lymphoma, or B-cell lymphoma.
In some embodiments, the malignancy is a solid tumor. B cells are optionally isolated from tumor tissue or surrounding tissue, or in some embodiments are isolated from peripheral blood.
The first population of B cells can be distinguished empirically from the second population of B cells by the affinity of the antibody produced for tumor cells or tumor antigens. The second population of B cells (the control population) can be from the same patient(s) as the first population, but isolated from non-tumor tissue, such as peripheral blood in some embodiments. The second population in some embodiments comprises B cells from patients who have a different tumor type or are non-cancerous, or in some embodiments are isolated from patients with the tumor type, but who are not mounting an effective antibody response.
Antibody gene sequencing, evaluation of antibody genetics, and cloning can be conducted as discussed elsewhere herein in the context of autoimmune disease. The antibodies or antigen-binding portions thereof are recombinantly produced and administered to patients to target the tumor for destruction or as an imaging reagent (e.g., with conjugated detectable label).
In some embodiments, the subject has an infectious disease, which may be caused by a bacteria, virus, fungus, or parasite. For example, B cells are isolated from infected tissue, or are isolated from peripheral blood or other suitable source. The first population of B cells can be distinguished from the second population of B cells by their affinity for pathogen cells or pathogen-associated antigens, and this process can
employ automated techniques using immobilized antigen in some embodiments. In some embodiments, the second population of B cells are from the same patient(s) as the first population, but are isolated from non-infected tissue or peripheral blood in some embodiments. In other embodiments, the second population comprises B cells from patients that do not display a productive immune response against the same pathogen, or are isolated from patients testing positive for a different (but optionally related) pathogen or non-pathogenic microbe. In some embodiments, the second population are isolated from healthy controls.
The antibodies or antigen-binding portions thereof are recombinantly produced and administered to one or more patients to target the pathogen.
In various embodiments, the pathogen may be a virus. Exemplary viruses include retroviruses (e.g., HIV), herpes simplex viruses (e.g, HSV-1, HSV-2, or varicella zoster), hepatitis viruses (e.g., HAV, HBV, HCV), adenovirus, HPV, Epstein- Barr Virus (EBV), Ebola, Marburg virus, and zika virus. In some embodiments, the infectious disease is a persistent or recurrent bacterial infection, such as that associated with pneumonia, bronchitis, sinusitis, vaginitis, enteritis, colitis, sepsis, or urinary tract infection. Exemplary bacterial pathogens for which the invention may be effective include species of Mycobacterium (including tuberculosis), Pseudomonas (e.g., Pseudomonas aeruginosa, as may occur in association with cystic fibrosis), Haemophilus (e.g., Haemophilus influenzae), Moraxella, Chlamydia, Neisseria, Streptococcus, Staphylococcus (including MRSA), Bordetella, Yersinia, and others.
Exemplary fungal or parasitic infections include Candidiasis (e.g., yeast vaginitis), malaria, trypanosomiasis, Aspergillus infection, toxoplasma, and Giardiasis. Modifications of the disclosed embodiments incorporating the spirit and substance of the invention may occur to persons skilled in the art and such modifications are within the scope of the present invention.
All references cited herein are hereby incorporated by reference in their entirety.
Claims
1. A method for treating an antibody-mediated autoimmune disease, the method comprising:
determining nucleotide sequences in a patient sample for a plurality of immunoglobulin-encoding genes or transcripts, the nucleotide sequences encoding at least a portion of the complementarity-determining region (CDR);
identifying one or more nucleotide sequences that correspond to the autoimmune disease;
synthesizing one or more oligonucleotides to reduce or inhibit the expression of said one or more nucleotide sequences; and
administering the one or more oligonucleotides to said patient.
2. The method of claim 1, wherein the antibody -mediated autoimmune disease is multiple sclerosis, neuromyelitis optica, optic neuritis, transverse myelitis, acute disseminated encephalitis, systemic lupus erythematosus (SLE), rheumatoid arthritis, Sjogren's disease, psoriasis, vasculitis, Crohn's disease, or inflammatory bowel disease.
3. The method of claim 1, wherein the antibody-mediated autoimmune disease is characterized by type II or type III hypersensitivity.
4. The method of claim 1, wherein the antibody mediated autoimmune disease is a demyelinating disease.
5. The method of claim 4, wherein the immunoglobulin-encoding genes or transcripts are VH4 genes or transcripts.
6. The method of claim 5, wherein the VH4 gene or transcript has at least two mutations with respect to the germline sequence at codons selected from 3 IB, 32, 40, 56, 57, 60, 81, and 89.
7. The method of claim 6, wherein the VH4 antibody binds to an antigen in human gray matter.
8. The method of claim 6 or 7, wherein the VH4 antibody has 3, 4, 5, or 6 mutations with respect to the germline sequence at codons selected from 3 IB, 32, 40, 56, 57, 60, 81, and 89.
9. The method of claim 8, wherein the VH4 antibody has mutations at two or more of codons 56, 57, and 81 with respect to the germline sequence, or at two or more of codons 40, 56, 81, and 89 with respect to the germline sequence.
10. The method of claim 8, wherein the VH4 antibody has mutations at one or more of codons 32, 40, 57, 60, and 89 with respect to the germline sequence.
11. The method of any one of claims 6 to 10, wherein the VH4 antibody has one or more of the following mutations:
codon 3 IB is R, N, D, P, K, G, A, or T, or is selected from R, N, and D;
codon 40 is S, L, or A;
codon 56 is selected from R, G, N, T, Y, H, D, and K, or is selected from N, T, and G;
codon 57 is A, I, D, S, or K, or is selected from A and I;
codon 81 is N, R, or M; and
codon 89 is selected from F, I, R, and L.
12. The method of claim 1 1, wherein the VH4 antibody has an R or N replacement at codon 81.
13. The method of claim 1 1, wherein the VH4 antibody has a T or R replacement at codon 56, optionally with the germline amino acid at codons 3 IB, 40, and 89, and which optionally binds astrocytes.
14. The method of any one of claims 5 to 13, wherein the VH4 germline is 4-04, 4- 28, 4-30, 4-31 , 4-34, 4-39, 4-59, 4-61 or 4-B.
15. The method of any one of claims 6 to 14, wherein the antibody has a set of mutations selected from Table 1.
16. The method of any one of claims 1 to 15, wherein the neurodegenerative disease is multiple sclerosis (MS).
17. The method of any one of claims 1 to 16, wherein the oligonucleotide is an antisense oligonucleotide.
18. The method of any one of claims 1 to 16, wherein the oligonucleotide is an siRNA.
19. The method of claim 17 or 18, wherein the oligonucleotide comprises one or more modifications selected from a locked nucleic acid, 2' nucleotide modification, back-bone modification, or base modification.
20. The method of any one of claims 1 to 19, wherein the oligonucleotide is formulated for administration by subcutaneous, intravenous, intramuscular, oral, or intrathecal administration.
21. The method of any one of claims 1 to 20, wherein the oligonucleotide is associated with a B-cell targeting ligand.
22. The method of claim 21, wherein the oligonucleotide is formulated in nanoparticles.
23. A method for making an active agent for treating an antibody-mediated autoimmune disease, the method comprising:
determining nucleotide sequences in a patient sample for a plurality of immunoglobulin-encoding genes or transcripts, the nucleotide sequences encoding at least a portion of the complementarity-determining region (CDR);
identifying one or more nucleotide sequences that correspond to the autoimmune disease;
synthesizing one or more oligonucleotides to reduce or inhibit the expression of said one or more nucleotide sequences; and
formulating the one or more oligonucleotides for administration to said patient.
24. The method of claim 23, wherein the antibody-mediated autoimmune disease is multiple sclerosis, neuromyelitis optica, optic neuritis, transverse myelitis, acute disseminated encephalitis, systemic lupus erythematosus (SLE), rheumatoid arthritis, Sjogren's disease, psoriasis, vasculitis, Crohn's disease, or inflammatory bowel disease.
25. The method of claim 24, wherein the antibody-mediated autoimmune disease is characterized by type II or type III hypersensitivity.
26. The method of claim 23, wherein the antibody-mediated autoimmune disease is a demy elinating disease.
27. The method of claim 26, wherein the immunoglobulin-encoding genes or transcripts are VH4 genes or transcripts.
28. The method of claim 27, wherein the VH4 gene or transcript has at least two mutations with respect to the germline sequence at codons selected from 3 IB, 32, 40, 56, 57, 60, 81, and 89.
29. The method of claim 28, wherein the VH4 antibody binds to an antigen in human gray matter.
30. The method of claim 28 or 29, wherein the VH4 antibody has 3, 4, 5, or 6 mutations with respect to the germline sequence at codons selected from 3 IB, 32, 40, 56, 57, 60, 81, and 89.
31. The method of claim 30, wherein the VH4 antibody has mutations at two or more of codons 56, 57, and 81 with respect to the germline sequence, or at two or more of codons 40, 56, 81, and 89 with respect to the germline sequence.
32. The method of claim 30, wherein the VH4 antibody has mutations at one or more of codons 32, 40, 57, 60, and 89 with respect to the germline sequence.
33. The method of any one of claims 28 to 32, wherein the VH4 antibody has one or more of the following mutations:
codon 3 IB is R, N, D, P, K, G, A, or T, or is selected from R, N, and D;
codon 40 is S, L, or A;
codon 56 is selected from R, G, N, T, Y, H, D, and K, or is selected from N, T, and G;
codon 57 is A, I, D, S, or K, or is selected from A and I;
codon 81 is N, R, or M; and
codon 89 is selected from F, I, R, and L.
34. The method of claim 33, wherein the VH4 antibody has an R or N replacement at codon 81.
35. The method of claim 33, wherein the VH4 antibody has a T or R replacement at codon 56, optionally with the germline amino acid at codons 3 IB, 40, and 89, and which optionally binds astrocytes.
36. The method of any one of claims 27 to 35, wherein the VH4 germline is 4-04, 4-28, 4-30, 4-31, 4-34, 4-39, 4-59, 4-61 or 4-B.
37. The method of any one of claims 28 to 36, wherein the antibody has a set of mutations selected from Table 1.
38. The method of any one of claims 26 to 37, wherein the demyelinating disease is multiple sclerosis (MS).
39. The method of any one of claims 26 to 38, wherein the oligonucleotide is an antisense oligonucleotide.
40. The method of any one of claims 26 to 38, wherein the oligonucleotide is an siRNA.
41. The method of claim 39 or 40, wherein the oligonucleotide comprises one or more modifications selected from a locked nucleic acid, 2' nucleotide modification, back-bone modification, or base modification.
42. The method of any one of claims 26 to 41, wherein the oligonucleotide is formulated for administration by subcutaneous, intravenous, intramuscular, oral, or intrathecal administration.
43. The method of any one of claims 26 to 42, wherein the oligonucleotide is associated with a B-cell targeting ligand.
44. The method of claim 43, wherein the oligonucleotide is formulated in nanoparticles.
45. A pharmaceutical formulation prepared by the method of any one of claims 26 to 44.
46. A method for treating an antibody-mediated autoimmune disease, the process comprising:
determining nucleotide sequences in a patient sample for a plurality of immunoglobulin-encoding genes or transcripts;
identifying one or more of the nucleotide sequences that correspond to the autoimmune disease;
producing antibodies or antigen-binding portions thereof encoded by one or more of the nucleotide sequences that correspond to the autoimmune disease; and administering the one or more antibodies or antigen-binding portions thereof to said patient to inhibit or reduce symptoms of said autoimmune disease.
47. The method of claim 46, wherein the antibody-mediated autoimmune disease is multiple sclerosis, neuromyelitis optica, optic neuritis, transverse myelitis, acute disseminated encephalitis, systemic lupus erythematosus (SLE), rheumatoid arthritis, Sjogren's disease, psoriasis, vasculitis, Crohn's disease, or inflammatory bowel disease.
48. The method of claim 47, wherein the antibody-mediated autoimmune disease is characterized by type II or type III hypersensitivity.
49. The method of claim 47, wherein the antibody-mediated autoimmune disease is a demyelinating disease.
50. The method of claim 49, wherein the immunoglobulin-encoding genes or transcripts are VH4 genes or transcripts.
51. The method of claim 50, wherein the VH4 gene or transcript has at least two mutations with respect to the germline sequence at codons selected from 3 IB, 32, 40, 56, 57, 60, 81, and 89.
52. The method of claim 51, wherein the VH4 antibody binds to an antigen in human gray matter.
53. The method of claim 51 or 52, wherein the VH4 antibody has 3, 4, 5, or 6 mutations with respect to the germline sequence at codons selected from 31B, 32, 40, 56, 57, 60, 81, and 89.
54. The method of claim 53, wherein the VH4 antibody has mutations at two or more of codons 56, 57, and 81 with respect to the germline sequence, or at two or more of codons 40, 56, 81, and 89 with respect to the germline sequence.
55. The method of claim 53, wherein the VH4 antibody has mutations at one or more of codons 32, 40, 57, 60, and 89 with respect to the germline sequence.
56. The method of any one of claims 51 to 55, wherein the VH4 antibody has one or more of the following mutations:
codon 3 IB is R, N, D, P, K, G, A, or T, or is selected from R, N, and D;
codon 40 is S, L, or A;
codon 56 is selected from R, G, N, T, Y, H, D, and K, or is selected from N, T, and G;
codon 57 is A, I, D, S, or K, or is selected from A and I;
codon 81 is N, R, or M; and
codon 89 is selected from F, I, R, and L.
57. The method of claim 56, wherein the VH4 antibody has an R or N replacement at codon 81.
58. The method of claim 56, wherein the VH4 antibody has a T or R replacement at codon 56, optionally with the germline amino acid at codons 3 IB, 40, and 89, and which optionally binds astrocytes.
59. The method of any one of claims 50 to 58, wherein the VH4 germline is 4-04, 4-28, 4-30, 4-31, 4-34, 4-39, 4-59, 4-61 or 4-B.
60. The method of any one of claims 51 to 59, wherein the antibody has a set of mutations selected from Table 1.
61. The method of any one of claims 49 to 60, wherein the demyelinating disease is multiple sclerosis (MS).
62. The method of any one of claims 46 to 61, wherein the antibody produced is an antibody lacking an Fc.
63. The method of claim 62, wherein the antibody is a F(ab')2 or Fab, a single chain antibody, or single chain variable fragment (scFv).
64. The method of any one of claims 46 to 63, wherein the antibody is formulated for administration by subcutaneous, intravenous, intramuscular, oral, or intrathecal administration.
65. A method for making an active agent for treating an antibody-mediated autoimmune disease, the process comprising:
determining nucleotide sequences in a patient sample for a plurality of immunoglobulin-encoding genes or transcripts;
identifying one or more of the nucleotide sequences that correspond to the autoimmune disease;
producing antibodies or antigen-binding portions thereof encoded by one or more of the nucleotide sequences that correspond to the autoimmune disease; and
formulating the one or more antibodies or antigen-binding portions thereof for delivery to said patient.
66. The method of claim 65, wherein the antibody-mediated autoimmune disease is multiple sclerosis, neuromyelitis optica, optic neuritis, transverse myelitis, acute disseminated encephalitis, systemic lupus erythematosus (SLE), rheumatoid arthritis, Sjogren's disease, psoriasis, vasculitis, Crohn's disease, or inflammatory bowel disease.
67. The method of claim 65, wherein the antibody-mediated autoimmune disease is characterized by type II or type III hypersensitivity.
68. The method of claim 66, wherein the antibody-mediated autoimmune disease is a demyelinating disease.
69. The method of claim 68, wherein the immunoglobulin-encoding genes or transcripts are VH4 genes or transcripts.
70. The method of claim 69, wherein the VH4 gene or transcript has at least two mutations with respect to the germline sequence at codons selected from 3 IB, 32, 40, 56, 57, 60, 81, and 89.
71. The method of claim 70, wherein the VH4 antibody binds to an antigen in human gray matter.
72. The method of claim 70 or 71, wherein the VH4 antibody has 3, 4, 5, or 6 mutations with respect to the germline sequence at codons selected from 3 IB, 32, 40, 56, 57, 60, 81, and 89.
73. The method of claim 72, wherein the VH4 antibody has mutations at two or more of codons 56, 57, and 81 with respect to the germline sequence, or at two or more of codons 40, 56, 81, and 89 with respect to the germline sequence.
74. The method of claim 72, wherein the VH4 antibody has mutations at one or more of codons 32, 40, 57, 60, and 89 with respect to the germline sequence.
75. The method of any one of claims 70 to 74, wherein the VH4 antibody has one or more of the following mutations:
codon 3 IB is R, N, D, P, K, G, A, or T, or is selected from R, N, and D;
codon 40 is S, L, or A;
codon 56 is selected from R, G, N, T, Y, H, D, and K, or is selected from N, T, and G;
codon 57 is A, I, D, S, or K, or is selected from A and I;
codon 81 is N, R, or M; and
codon 89 is selected from F, I, R, and L.
76. The method of claim 75, wherein the VH4 antibody has an R or N replacement at codon 81.
77. The method of claim 75, wherein the VH4 antibody has a T or R replacement at codon 56, optionally with the germline amino acid at codons 3 IB, 40, and 89, and which optionally binds astrocytes.
78. The method of any one of claims 69 to 77, wherein the VH4 germline is 4-04, 4-28, 4-30, 4-31, 4-34, 4-39, 4-59, 4-61 or 4-B.
79. The method of any one of claims 70 to 78, wherein the antibody has a set of mutations selected from Table 1.
80. The method of any one of claims 68 to 79, wherein the autoimmune disease is multiple sclerosis (MS).
81. The method of any one of claims 65 to 70, wherein the antibody produced is an antibody lacking an Fc.
82. The method of claim 81, wherein the antibody is a F(ab')2 or Fab, a single chain antibody, or single chain variable fragment (scFv).
83. The method of any one of claims 65 to 82, wherein the oligonucleotide is formulated for administration by subcutaneous, intravenous, intramuscular, oral, or intrathecal administration.
84. A pharmaceutical formulation prepared by the method of any one of claims 65 to 83.
85. A method for producing a therapeutic antibody, comprising:
providing a first population of B cells from one or more subj ects displaying an immune response against a malignancy or infectious disease, and a second population of B cells that do not display said immune response;
determining nucleotide sequences for a plurality of immunoglobulin-encoding genes or transcripts;
identifying one or more of the nucleotide sequences that correspond to the immune response; and
producing recombinant antibodies or antigen-binding portions thereof encoded by one or more of the nucleotide sequences that correspond to the immune response.
86. The method of claim 85, wherein the B cells displaying an immune response are from a patient having a malignancy.
87. The method of claim 86, wherein the malignancy is squamous or basal cell carcinoma, melanoma, biliary tract cancer, bladder cancer, bone cancer, brain or central nervous system cancer, breast cancer, cancer of the peritoneum, cervical cancer, colon or rectum cancer, cancer of the digestive system, endometrial cancer, esophageal cancer, eye cancer, cancer of the head and neck, gastric cancer, glioblastoma, neuroblastoma, liver cancer, kidney cancer, larynx cancer, leukemia, lung cancer, small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, mesothelioma, myeloma, oral cavity cancer, ovarian cancer, pancreatic cancer, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland carcinoma, testicular cancer, thyroid cancer, uterine cancer, lymphoma, Hodgkin's lymphoma, non- Hodgkin's lymphoma, Cutaneous T-Cell Lymphoma, or B-cell lymphoma.
88. The method of claim 86 or 87, wherein the malignancy is a solid tumor.
89. The method of claim 88, wherein B cells are isolated from tumor tissue.
90. The method of any one of claims 85 to 89, wherein B cells are isolated from peripheral blood.
91. The method of any one of claims 85 to 90, wherein the first population of B cells are distinguished from the second population of B cells by their affinity for tumor cells or antigens.
92. The method of claim 91, wherein the second population of B cells are from the same patient(s) as the first population.
93. The method of claim 91, wherein the second population comprises B cells from patients that do not display an immune response against the tumor type.
94. The method of any one of claims 87 to 93, wherein the antibodies or antigen- binding portions thereof are recombinantly produced and administered to said patient(s) to target the tumor for destruction or as an imaging reagent.
95. The method of any one of claims 87 to 93, wherein the antibodies or antigen- binding portions thereof are recombinantly produced and administered to patients with the same tumor type for tumor destruction or as an imaging reagent.
96. The method of claim 85, wherein the subjects have an infectious disease.
97. The method of claim 96, wherein the infectious disease is a bacteria, virus, fungus, or parasite.
98. The method of claim 96 or 97, wherein the B cells are isolated from infected tissue.
99. The method of any one of claims 96 to 98, wherein B cells are isolated from peripheral blood.
100. The method of any one of claims 96 to 99, wherein the first population of B cells are distinguished from the second population of B cells by their affinity for pathogen cells or antigens.
101. The method of claim 100, wherein the second population of B cells are from the same patient(s) as the first population.
102. The method of claim 100, wherein the second population comprises B cells from patients that do not display a productive immune response against the pathogen.
103. The method of any one of claims 96 to 102, wherein the antibodies or antigen- binding portions thereof are produced and administered to one or more patients to target the pathogen.
104. The method of any one of claims 85 to 103, wherein nucleotide sequences are evaluated based on heavy or light chain gene families, V-D-J usage, and mutations within the heavy and/or light chain as compared to the germline sequence.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/301,073 US20190183934A1 (en) | 2016-05-13 | 2017-05-15 | Treatment of disease based on immune cell sequencing |
US17/340,196 US20210290681A1 (en) | 2016-05-13 | 2021-06-07 | Treatment of disease based on immune cell sequencing |
US17/576,046 US20220133800A1 (en) | 2016-05-13 | 2022-01-14 | Treatment of disease based on immune cell sequencing |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662336017P | 2016-05-13 | 2016-05-13 | |
US62/336,017 | 2016-05-13 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/301,073 A-371-Of-International US20190183934A1 (en) | 2016-05-13 | 2017-05-15 | Treatment of disease based on immune cell sequencing |
US17/340,196 Continuation US20210290681A1 (en) | 2016-05-13 | 2021-06-07 | Treatment of disease based on immune cell sequencing |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017197376A1 true WO2017197376A1 (en) | 2017-11-16 |
Family
ID=60266854
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2017/032593 WO2017197376A1 (en) | 2016-05-13 | 2017-05-15 | Treatment of disease based on immune cell sequencing |
Country Status (2)
Country | Link |
---|---|
US (3) | US20190183934A1 (en) |
WO (1) | WO2017197376A1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015070009A2 (en) * | 2013-11-08 | 2015-05-14 | The Board Of Regents Of The University Of Texas System | Vh4 antibodies against gray matter neuron and astrocyte |
-
2017
- 2017-05-15 WO PCT/US2017/032593 patent/WO2017197376A1/en active Application Filing
- 2017-05-15 US US16/301,073 patent/US20190183934A1/en not_active Abandoned
-
2021
- 2021-06-07 US US17/340,196 patent/US20210290681A1/en not_active Abandoned
-
2022
- 2022-01-14 US US17/576,046 patent/US20220133800A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015070009A2 (en) * | 2013-11-08 | 2015-05-14 | The Board Of Regents Of The University Of Texas System | Vh4 antibodies against gray matter neuron and astrocyte |
Non-Patent Citations (3)
Title |
---|
ANDERSON, JM ET AL.: "Issues and Perspectives on the Biocompatibility and Immunotoxicity Evaluation of Implanted Controlled Release Systems", JOURNAL OF CONTROLLED RELEASE, vol. 57, no. 2, 1 February 1999 (1999-02-01), pages 107 - 113, XP004157768 * |
BAUMGARTH, N: "How Specific is too Specific? B- cell Responses to Viral infections Reveal the Importance of Breadth over Depth", IMMUNOLOGICAL REVIEWS, vol. 255, no. 1, September 2013 (2013-09-01), pages 82 - 94, XP055440294 * |
FREMD, C ET AL.: "B Cell-Regulated Immune Responses in Tumor Models and Cancer Patients", ONCOIMMUNOLOGY, vol. 2, no. 7, 1 July 2013 (2013-07-01), pages e25443 - 1-9, XP055440293 * |
Also Published As
Publication number | Publication date |
---|---|
US20210290681A1 (en) | 2021-09-23 |
US20190183934A1 (en) | 2019-06-20 |
US20220133800A1 (en) | 2022-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4159757A1 (en) | Sars-cov-2 spike protein binding molecule and application thereof | |
JP5805393B2 (en) | Antibody to CSF-1R | |
von Büdingen et al. | Clonally expanded plasma cells in the cerebrospinal fluid of MS patients produce myelin‐specific antibodies | |
EP2948777B1 (en) | Dipeptide-repeat proteins as therapeutic target in neurodegenerative diseases with hexanucleotide repeat expansion | |
CN108220297A (en) | For generating the method for monoclonal antibody and reagent | |
JP2021061852A (en) | Method of improving characteristic of protein | |
JP2021167353A (en) | Compositions and methods for treating autoimmune diseases and cancers | |
JP6628787B2 (en) | Antagonistic anti-OX40L antibodies and methods of using them | |
EP4144758A1 (en) | Single variable domain antibody targeting human programmed death ligand 1 (pd-l1) and derivative thereof | |
CN111848798A (en) | Nano antibody capable of being combined with BCMA (brain cell activating antigen) and application thereof | |
WO2017117331A1 (en) | Methods for identifying and treating hemoglobinopathies | |
CN110621695B (en) | anti-JAGGED 1 antigen binding proteins | |
AU2019334864A1 (en) | Conditionally active chimeric antigen receptors for modified T-cells | |
US20220133800A1 (en) | Treatment of disease based on immune cell sequencing | |
US20210309716A1 (en) | Chimeric antigen receptor | |
US20220372551A1 (en) | Methods for identification of ligand-blocking antibodies and for determining antibody potency | |
CN109563490A (en) | Herpesviral with modified Glycoprotein B | |
JP2019518724A (en) | Treatment of Respiratory Disease by Targeting Interleukin 4 Induction 1 (IL4I1) | |
CN115724968A (en) | VEGF binding molecules and uses thereof | |
CN114057871A (en) | Anti-human peroxistin monoclonal chimeric antibody and application thereof | |
WO2019183437A1 (en) | Methods and compositions for antibody to high affinity receptor for ige | |
CN106916224B (en) | Monoclonal antibody for resisting B lymphocyte stimulating factor and its prepn and use | |
US11999778B2 (en) | VH4 antibodies and compositions comprising the same | |
CN115894691A (en) | ROR 1-targeted antigen binding proteins | |
US20220195024A1 (en) | Monoclonal Antibodies to ELTD1 and Uses Thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17797014 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17797014 Country of ref document: EP Kind code of ref document: A1 |